Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-let-7a-5p EZH2 -1.37 0 2.64 0 miRNAWalker2 validate; miRNATAP -0.62 0 NA
2 hsa-let-7b-5p EZH2 -1.62 0 2.64 0 miRNATAP -0.56 0 25611389 Significant inverse correlation between EZH2 and hsa-miR-26a-5p R2=0.56 P=0.0001 and hsa-let-7b-5p R2=0.19 P=0.02 expression was observed in the same samples corroborating the belief of EZH2 being a bona fide target for these two miRNAs in CRC
3 hsa-let-7d-5p EZH2 -0.62 6.0E-5 2.64 0 miRNATAP -0.22 0.00552 NA
4 hsa-let-7e-5p EZH2 -0.75 7.0E-5 2.64 0 miRNATAP -0.35 0 NA
5 hsa-let-7f-5p EZH2 -0.05 0.83408 2.64 0 miRNATAP -0.23 0 NA
6 hsa-let-7g-5p EZH2 0.08 0.58308 2.64 0 miRNATAP -0.26 0.00081 NA
7 hsa-miR-101-3p EZH2 1.39 0 2.64 0 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.18 0.00042 25428391; 22977606; 24002871; 26718325; 26251675; 22108826; 24490857; 23962556; 21818714; 25260883; 24211739; 27620004; 22450781; 25400732; 25190211; 24807198; 21321380; 22094936; 21270667 The results showed that mir-101 was down-regulated and EZH2 were upregulated; Subsequently the roles of mir-101 and EZH2 in tumor growth and progression in vitro were tested; Overexpression of mir-101 mimics was able to suppress the expression of EZH2 in XWLC-05 cells; Interleukin-1β subsequently induces the downregulation of mir-101 which may result in the upregulated level of EZH2 and occurrence of lung cancer;Therefore we aimed to ascertain whether or not the overexpression of miR-101 inhibits invasion of lung cancer through regulation of EZH2; In this study the expression of miR-101 was down-regulated and the expression of EZH2 was up-regulated in lung cancer; Overexpression of miR-101 induced a marked reduction in EZH2 mRNA levels in several lung cancer cell lines; miR-101 may be a potent tumor suppressor by altering chromatin structure through repression of EZH2 and may be a potential therapeutic tool for patients with lung cancer;miR-101 in turn inhibits the expression of two subunits of PRC2 EZH2 and EED thus creating a double-negative feedback loop that regulates the process of hepatocarcinogenesis; In addition co-overexpression of c-Myc and EZH2 in HCC samples was closely associated with lower expression of miR-101 P < 0.0001 and poorer prognosis of HCC patients P < 0.01;Reporter gene assays revealed that ectopic expression of EZH2 inhibited the transcriptional activities of miR-101-1 promoter; Moreover our results also demonstrated that similar antitumor effects can be achieved either by ectopic miR-101 or EZH2 silencing in HCC cells; These findings show that elevated EZH2 contributes to miR-101 deregulation in HCC and highlight the coordinated role of miR-101 and EZH2 in hepatocarcinogenesis;MiR-101 is a microRNA involved in a negative feedback circuit with EZH2 in different normal and tumor tissues; To that miR-101 can behave as a tumor suppressor in several cancers by repressing EZH2 expression; We therefore evaluated whether miR-101 is de-regulated in eRMS and investigated its interplaying with EZH2 as well as its role in the in vitro tumorigenic potential of these tumor cells; Herein we report that miR-101 is down-regulated in eRMS patients and in tumor cell lines compared to their controls showing an inverse pattern of expression with EZH2; We also show that miR-101 is up-regulated in eRMS cells following both genetic and pharmacological inhibition of EZH2; In turn miR-101 forced expression reduces EZH2 levels as well as restrains the migratory potential of eRMS cells and impairs their clonogenic and anchorage-independent growth capabilities; This phenomenon is associated to reduced H3K27me3 levels at the same regulatory locus indicating that EZH2 directly targets miR-101 for repression in eRMS cells; Altogether our data show that in human eRMS miR-101 is involved in a negative feedback loop with EZH2 whose targeting has been previously shown to halt eRMS tumorigenicity;Mechanistic investigations revealed that reexpression of miR-101 was sufficient to limit the expression of EZH2 and the proinvasive cell surface adhesion molecule EpCAM;Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid induced apoptosis through down regulation of EZH2 expression by miR 101; Furthermore treatment of bladder cancer cells with a combination of GA and MJ induced synergistic inhibition of the enhancer of zeste homologue 2 EZH2 expression whereas miR-101 expression was up-regulated; Conversely knockdown of miR-101 restored this decreased expression of EZH2 and suppressed the inhibitory effect of GA and MJ on the growth of bladder cancer cells; MJ sensitizes bladder cancer cells to GA-induced apoptosis by down-regulating the expression of EZH2 induced by miR-101;MiR 101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2; Functional assays showed that miR-101 suppressed invasion and proliferation - an outcome that could be phenocopied by siRNA knockdown of MITF and EZH2;We explore the role of miR-101 and its interaction with EzH2 in epithelial ovarian carcinoma EOC; CHIP assays revealed that re-expression of miR-101 inhibited the interaction of EzH2 with p21waf1/cip1 promoter;miR 101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer; miR-101 overexpression decreased the expression of EZH2 reduced proliferation and migration of ovarian cancer cells and resensitized drug-resistant cancer cells to cisplatin-induced cytotoxicity suggesting the important role miR-101 plays in ovarian cancer that may be associated with its function as a regulator targeting EZH2;The aim of our study was to investigate the functional role of both miR-101 and EZH2 in human hepatocellular carcinoma HCC; MiR-101 and EZH2 expressions were evaluated in tumor tissues of 99 HCC patients and 7 liver cancer cell lines by real-time PCR; Luciferase reporter assay was employed to validate whether EZH2 represents a target gene of miR-101; MiR-101 expression was significantly downregulated in most of HCC tissues and all cell lines whereas EZH2 was significantly overexpressed in most of HCC tissues and all cell lines; There was a negative correlation between expression levels of miR-101 and EZH2; Luciferase assay results confirmed EZH2 as a direct target gene of miR-101 which negatively regulates EZH2 expression in HCC; Tumor suppressor miR-101 represses HCC progression through directly targeting EZH2 oncogene and sensitizes liver cancer cells to chemotherapeutic treatment;Long non coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR 101 to modulate EZH2 expression;Moreover around 40% of cases showing miR-101 down-regulation displayed concomitant EZH2 over-expression at the RNA and protein levels which in turn was associated with loss/aberrant expression of E-cadherin; In conclusion we show that deletions and/or microdeletions at both miR-101 genomic loci cause mature miR-101 down-regulation subsequent EZH2 over-expression and E-cadherin dysfunction specifically in intestinal-type GC;miR 101 suppresses tumor proliferation and migration and induces apoptosis by targeting EZH2 in esophageal cancer cells; The expression level of miR-101 was inversely correlated to EZH2 protein expression in ESCC cell; These findings suggest that decreased expression of miR-101 might promote metastasis of human ESCC by inducing accumulation of EZH2 protein;In the present study we reported that ectopic overexpression of miR-101 downregulated the expression level of EZH2 and significantly inhibited migration and invasion of osteosarcoma cells; In addition knockdown of EZH2 by siRNA showed the same effect of miR-101 on migration and invasion; To conclude these results indicate that miR-101 may act as a tumor suppressor in osteosarcoma as it has a suppressive role in cell migration and invasion by targeting EZH2;MiR 101 downregulated in retinoblastoma functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2; Finally we found that miR-101 directly inhibited EZH2 expression by targeting its 3'-UTR and EZH2 was upregulated and inversely correlated with miR-101 expression in the retinoblastoma tissues; Thus for the first time we provide convincing evidence that downregulation of miR-101 is associated with tumor aggressiveness in retinoblastoma and inhibits cell growth and proliferation of retinoblastoma cells by targeting EZH2;miR 101 is down regulated in glioblastoma resulting in EZH2 induced proliferation migration and angiogenesis; Here we determined that miR-101 is down-regulated in GBM resulting in overexpression of the miR-101 target PcG protein EZH2 a histone methyltransferase affecting gene expression profiles in an epigenetic manner; Our results indicate that EZH2 has a versatile function in GBM progression and that its overexpression is at least partly due to decreased miR-101 expression;Main objective of the present study is to investigate miR-26a and miR-101 levels which both target EZH2 for their association with molecular pathways and with efficacy of tamoxifen as first-line monotherapy for metastatic breast cancer;In this study we investigate whether miRNA miR-101 regulates EZH2 expression in NSCLC; We evaluated the expression of miR-101 and EZH2 in 20 matched NSCLC and adjacent nontumor lung tissues by reverse-transcriptase polymerase chain reaction and immunohistochemistry respectively; Luciferase reporter assay was used to determine whether miR-101 directly targets EZH2; To assess the effect of miR-101 on NSCLC biological behavior cell proliferation invasion and response to chemotherapy were analyzed using NSCLC cells transfected with miR-101 mimics or transfected with specific small interfering RNA to deplete EZH2 small interfering RNA-EZH2; Reduced expression of miR-101 was associated with overexpression of EZH2 in NSCLC tumor tissues; Transfection of miR-101 mimics significantly suppressed the activity of the luciferase reporter containing wild type but not mutant EZH2 3'-UTR and decreased EZH2 expression in NSCLC cell lines; Therapeutic strategies to rescue miR-101 expression or silence EZH2 may be beneficial to patients with NSCLC in the future
8 hsa-miR-139-5p EZH2 -2.27 0 2.64 0 miRanda -0.3 0 NA
9 hsa-miR-150-3p EZH2 -2.18 0 2.64 0 MirTarget; miRNATAP -0.16 0 NA
10 hsa-miR-214-3p EZH2 -1.11 4.0E-5 2.64 0 miRNAWalker2 validate; miRTarBase -0.18 5.0E-5 21828058; 22867052; 22962603 Decreased microRNA 214 levels in breast cancer cells coincides with increased cell proliferation invasion and accumulation of the Polycomb Ezh2 methyltransferase; We have shown previously that miR-214 regulates Ezh2 in skeletal muscle and embryonic stem cells; MiR-214 expression was inversely correlated with Ezh2 mRNA and protein levels in breast cancer cell lines and at least one copy of the miR-214 alleles was found to be deleted in 24% 6/25 of primary breast tumors; Experimental increase of miR-214 in breast cancer cell lines correlated with reduction of Ezh2 protein levels a known marker of invasion and aggressive breast cancer behavior; Supporting a direct targeting mechanism miR-214 decreased luciferase activity from a construct containing the Ezh2 3' untranslated region; These findings indicate that reduced miR-214 levels may contribute to breast tumorigenesis by allowing abnormally elevated Ezh2 accumulation and subsequent unchecked cell proliferation and invasion;In Eca109 cells overexpression of miR-98 and miR-214 significantly inhibited the migration and invasion of ESCC cells which was reversed by transfection of EZH2; These findings suggest that decreased expression of miR-98 and miR-214 might promote metastasis of human ESCC by inducing accumulation of EZH2 protein;The enhancer of zeste homologue 2 EZH2 and β-catenin CTNNB1 was identified as two potential direct downstream targets of miR-214 through bioinformatics analysis and experimentally validated the miRNA-target interactions with a dual-firefly luciferase reporter assay; Furthermore the silencing of miR-214 or overexpression of EZH2 increased EpCAM+ stem-like cells through the activation of CTNNB1
11 hsa-miR-26a-5p EZH2 -0.13 0.44003 2.64 0 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.55 0 20952513; 23750239; 25611389; 24452597; 26733151; 21901171; 25494962; 27517917; 22086681; 27562865; 22930729; 22094936 Pathologically decreased miR 26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer; Subsequently MTDH and EZH2 are identified as two direct targets of miR-26a and they are significantly upregulated in breast cancer; MCF7 xenografts with exogenous miR-26a show that a decrease in expression of both MTDH and EZH2 is accompanied by an increase in apoptosis; Our findings suggest that miR-26a functionally antagonizes human breast carcinogenesis by targeting MTDH and EZH2;MiR-26a has been reported as a tumor suppressor microRNA in breast cancer which is attributed mainly to targeting of MTDH and EZH2 however the expression profile and therapeutic potential of miR-26a is still unclear;Significant inverse correlation between EZH2 and hsa-miR-26a-5p R2=0.56 P=0.0001 and hsa-let-7b-5p R2=0.19 P=0.02 expression was observed in the same samples corroborating the belief of EZH2 being a bona fide target for these two miRNAs in CRC;Moreover EZH2 was upregulated and inversely correlated with miR-26a expression in the osteosarcoma tissues; Thus for the first time we provide convincing evidence that downregulation of miR-26a is associated with tumor aggressiveness and tumor metastasis and miR-26a inhibits cell migration and invasion by targeting the EZH2 gene in osteosarcoma;Through down-regulation of EZH2 expression and up-regulation of E-cadherin expression miR-26a inhibited the EMT process in vitro and in vivo; Luciferase reporter assay showed that miR-26a directly interacted with EZH2 messenger RNA mRNA; Furthermore the expression of miR-26a was positively correlated with E-cadherin expression and inversely correlated with EZH2 expression in human HCC tissue; miR-26a inhibited the EMT process in HCC by down-regulating EZH2 expression;Previously EZH2 was shown to be regulated by miR-26a at the translational levels in lymphomas;miR 26a promoted by interferon alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2; Here we report that the IFN-α-induced microRNA-26a miR-26a can inhibit HCC proliferation and invasion by suppressing enhancer of zeste homologue 2 EZH2 expression in tumor cells; It was shown that there was increased miR-26a accompanied with downregulated EZH2 expression in the HCC specimens and EZH2 mRNA levels were inversely correlated with miR-26a expression; In addition the miR-26a mimic transfection decreased the EZH2 expression level significantly in the transfected HepG2 cells and inhibited HepG2 cell proliferation and invasion effectively; Our results indicate that miR-26a exerts growth inhibition in HCC and that its inhibitory effect is mediated briefly by blocking EZH2 expression;miR-26a inhibition partly prevents the metformin viability effect and the PTEN and EZH2 expression reduction;We also found that reexpression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in pancreatic cancer cells;In the present study the influence of miR-26a and miR-138 on EZH2 and cellular function including the impact on the cell cycle regulating network was evaluated in PCa cells; The present findings suggest an anti-proliferative role for miR-26a and miR-138 in PCa by blocking the G1/S-phase transition independent of EZH2 but via a concerted inhibition of crucial cell cycle regulators;We propose the hypermethylation of miR-26a as an alternative pathway of ERG rearrangement-independent EZH2 activation;High miR 26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer; Main objective of the present study is to investigate miR-26a and miR-101 levels which both target EZH2 for their association with molecular pathways and with efficacy of tamoxifen as first-line monotherapy for metastatic breast cancer; Cell cycle regulation and CCNE1 and CDC2 were the only significant overlapping pathway and genes differentially expressed between tumors with high and low levels of miR-26a and EZH2 respectively; Cell cycle regulation is the only overlapping pathway linked to miR-26a and EZH2 levels; Low mRNA levels of EZH2 CCNE1 and CDC2 and high levels of miR-26a are associated with favorable outcome on tamoxifen
12 hsa-miR-30d-5p EZH2 -0.92 4.0E-5 2.64 0 miRNAWalker2 validate; miRTarBase -0.42 0 22399519 Down regulation of the miR 25 and miR 30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2; We report that miR-25 and miR-30d target the polycomb protein enhancer of zeste 2 EZH2 that has oncogenic activity and is drastically up-regulated in anaplastic thyroid carcinomas but not in the differentiated ones; The down-regulation of miR-25 and miR-30d could contribute to the process of thyroid cancer progression leading to the development of anaplastic carcinomas targeting EZH2 mRNA
13 hsa-miR-320a EZH2 -0.96 0 2.64 0 miRNAWalker2 validate -0.34 0 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 POSITIVE REGULATION OF GENE EXPRESSION 90 1733 3.197e-37 1.048e-33
2 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 91 1784 4.504e-37 1.048e-33
3 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 88 1805 3.667e-34 5.687e-31
4 TISSUE DEVELOPMENT 80 1518 5.082e-33 5.912e-30
5 REGULATION OF CELL DIFFERENTIATION 79 1492 1.057e-32 9.832e-30
6 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 75 1395 2.584e-31 2.004e-28
7 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 68 1142 8.21e-31 5.457e-28
8 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 64 1004 1.411e-30 8.207e-28
9 NEGATIVE REGULATION OF GENE EXPRESSION 76 1493 3.358e-30 1.736e-27
10 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 54 740 1.762e-28 8.197e-26
11 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 77 1672 9.094e-28 3.847e-25
12 TUBE DEVELOPMENT 47 552 1.22e-27 4.73e-25
13 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 80 1848 3.657e-27 1.309e-24
14 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 72 1517 1.367e-26 4.545e-24
15 TUBE MORPHOGENESIS 37 323 2.391e-26 7.417e-24
16 ORGAN MORPHOGENESIS 54 841 9.152e-26 2.662e-23
17 POSITIVE REGULATION OF CELL DIFFERENTIATION 53 823 2.456e-25 6.723e-23
18 EPITHELIUM DEVELOPMENT 55 945 3.537e-24 9.144e-22
19 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 65 1360 5.502e-24 1.347e-21
20 RESPONSE TO ENDOGENOUS STIMULUS 67 1450 6.025e-24 1.402e-21
21 RESPONSE TO LIPID 53 888 8.751e-24 1.939e-21
22 RESPONSE TO OXYGEN CONTAINING COMPOUND 64 1381 7.105e-23 1.475e-20
23 CELL DEVELOPMENT 65 1426 7.29e-23 1.475e-20
24 CARDIOVASCULAR SYSTEM DEVELOPMENT 49 788 9.92e-23 1.846e-20
25 CIRCULATORY SYSTEM DEVELOPMENT 49 788 9.92e-23 1.846e-20
26 RESPONSE TO ORGANIC CYCLIC COMPOUND 52 917 2.576e-22 4.61e-20
27 GLAND DEVELOPMENT 36 395 3.239e-22 5.581e-20
28 NEGATIVE REGULATION OF CELL COMMUNICATION 57 1192 6.519e-21 1.083e-18
29 REGULATION OF CELL DEATH 63 1472 1.067e-20 1.713e-18
30 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 52 1008 1.77e-20 2.746e-18
31 CELL PROLIFERATION 43 672 2.027e-20 3.039e-18
32 RESPONSE TO HORMONE 49 893 2.09e-20 3.039e-18
33 NEUROGENESIS 61 1402 2.299e-20 3.242e-18
34 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 46 801 6.112e-20 8.365e-18
35 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 50 957 6.475e-20 8.607e-18
36 UROGENITAL SYSTEM DEVELOPMENT 30 299 8.136e-20 1.052e-17
37 REGULATION OF CELL PROLIFERATION 62 1496 1.195e-19 1.503e-17
38 NEGATIVE REGULATION OF CELL DIFFERENTIATION 40 609 2.033e-19 2.489e-17
39 MORPHOGENESIS OF AN EPITHELIUM 33 400 4.393e-19 5.241e-17
40 RESPONSE TO STEROID HORMONE 36 497 6.736e-19 7.835e-17
41 TISSUE MORPHOGENESIS 37 533 8.611e-19 9.539e-17
42 VASCULATURE DEVELOPMENT 35 469 8.421e-19 9.539e-17
43 NEGATIVE REGULATION OF CELL DEATH 46 872 1.753e-18 1.897e-16
44 IMMUNE SYSTEM DEVELOPMENT 38 582 2.208e-18 2.335e-16
45 EMBRYO DEVELOPMENT 46 894 4.631e-18 4.789e-16
46 NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 48 983 6.308e-18 6.381e-16
47 EMBRYONIC MORPHOGENESIS 36 539 9.264e-18 9.171e-16
48 CELL FATE COMMITMENT 25 227 1.219e-17 1.181e-15
49 RESPONSE TO ALCOHOL 30 362 1.786e-17 1.696e-15
50 SKELETAL SYSTEM DEVELOPMENT 33 455 2.143e-17 1.995e-15
51 EPITHELIAL CELL DIFFERENTIATION 34 495 3.532e-17 3.222e-15
52 CENTRAL NERVOUS SYSTEM DEVELOPMENT 44 872 5.716e-17 5.114e-15
53 REGULATION OF PROTEIN MODIFICATION PROCESS 62 1710 8.396e-17 7.371e-15
54 REGULATION OF WNT SIGNALING PATHWAY 27 310 2.327e-16 2.005e-14
55 MUSCLE STRUCTURE DEVELOPMENT 31 432 2.93e-16 2.478e-14
56 NEURON DIFFERENTIATION 43 874 3.394e-16 2.82e-14
57 REGULATION OF CANONICAL WNT SIGNALING PATHWAY 24 236 3.535e-16 2.885e-14
58 EMBRYONIC ORGAN DEVELOPMENT 30 406 4.162e-16 3.339e-14
59 TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 39 724 5.067e-16 3.996e-14
60 CONNECTIVE TISSUE DEVELOPMENT 22 194 6.364e-16 4.935e-14
61 BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE 19 131 6.472e-16 4.937e-14
62 FOREBRAIN DEVELOPMENT 28 357 9.39e-16 7.047e-14
63 CELLULAR COMPONENT MORPHOGENESIS 43 900 9.657e-16 7.132e-14
64 MAMMARY GLAND DEVELOPMENT 18 117 1.319e-15 9.59e-14
65 REGULATION OF GROWTH 36 633 1.466e-15 1.049e-13
66 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 48 1152 3.162e-15 2.229e-13
67 HEART MORPHOGENESIS 22 212 4.177e-15 2.901e-13
68 KIDNEY EPITHELIUM DEVELOPMENT 18 125 4.393e-15 3.006e-13
69 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 32 513 4.991e-15 3.366e-13
70 RESPONSE TO INORGANIC SUBSTANCE 31 479 5.082e-15 3.378e-13
71 RESPONSE TO EXTERNAL STIMULUS 61 1821 6.307e-15 4.133e-13
72 DIGESTIVE SYSTEM DEVELOPMENT 19 148 6.539e-15 4.226e-13
73 REGULATION OF PHOSPHORUS METABOLIC PROCESS 57 1618 7.351e-15 4.685e-13
74 BLOOD VESSEL MORPHOGENESIS 27 364 1.247e-14 7.839e-13
75 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 39 799 1.276e-14 7.917e-13
76 MAMMARY GLAND MORPHOGENESIS 12 40 1.519e-14 9.303e-13
77 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 44 1021 1.708e-14 1.032e-12
78 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 22 229 2.098e-14 1.252e-12
79 POSITIVE REGULATION OF RESPONSE TO STIMULUS 62 1929 2.358e-14 1.389e-12
80 REGULATION OF DEVELOPMENTAL GROWTH 24 289 3.394e-14 1.974e-12
81 OUTFLOW TRACT MORPHOGENESIS 13 56 4.776e-14 2.744e-12
82 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 53 1492 5.96e-14 3.382e-12
83 MORPHOGENESIS OF A BRANCHING STRUCTURE 19 167 6.188e-14 3.469e-12
84 CARTILAGE DEVELOPMENT 18 147 7.97e-14 4.415e-12
85 IMMUNE SYSTEM PROCESS 62 1984 8.434e-14 4.617e-12
86 DEVELOPMENTAL GROWTH 25 333 9.664e-14 5.229e-12
87 MUSCLE TISSUE DEVELOPMENT 23 275 1.026e-13 5.489e-12
88 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 29 465 1.062e-13 5.617e-12
89 HEART DEVELOPMENT 29 466 1.122e-13 5.864e-12
90 RESPIRATORY SYSTEM DEVELOPMENT 20 197 1.18e-13 6.099e-12
91 EMBRYONIC ORGAN MORPHOGENESIS 23 279 1.394e-13 7.129e-12
92 REPRODUCTIVE SYSTEM DEVELOPMENT 27 408 1.961e-13 9.919e-12
93 REGULATION OF HEMOPOIESIS 24 314 2.101e-13 1.051e-11
94 POSITIVE REGULATION OF DEVELOPMENTAL GROWTH 18 156 2.265e-13 1.121e-11
95 CELLULAR RESPONSE TO HORMONE STIMULUS 31 552 2.311e-13 1.132e-11
96 NEPHRON DEVELOPMENT 16 115 2.648e-13 1.284e-11
97 REGULATION OF CELL DEVELOPMENT 38 836 2.685e-13 1.288e-11
98 LEUKOCYTE DIFFERENTIATION 23 292 3.643e-13 1.73e-11
99 RESPONSE TO WOUNDING 31 563 3.891e-13 1.829e-11
100 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 32 602 4.063e-13 1.891e-11
101 CELLULAR RESPONSE TO LIPID 28 457 4.503e-13 2.074e-11
102 POSITIVE REGULATION OF CELL PROLIFERATION 37 814 5.769e-13 2.619e-11
103 MOVEMENT OF CELL OR SUBCELLULAR COMPONENT 47 1275 5.797e-13 2.619e-11
104 MAMMARY GLAND EPITHELIUM DEVELOPMENT 12 53 6.37e-13 2.85e-11
105 REGULATION OF CELL CYCLE 40 949 6.512e-13 2.886e-11
106 DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS 15 104 8.746e-13 3.839e-11
107 POSITIVE REGULATION OF CELL DEVELOPMENT 28 472 9.859e-13 4.287e-11
108 HEAD DEVELOPMENT 34 709 1.277e-12 5.503e-11
109 POSITIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT 12 56 1.294e-12 5.522e-11
110 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 30 554 1.474e-12 6.225e-11
111 LOCOMOTION 43 1114 1.487e-12 6.225e-11
112 GROWTH 26 410 1.498e-12 6.225e-11
113 RESPONSE TO CORTICOSTEROID 18 176 1.832e-12 7.545e-11
114 RESPONSE TO OXIDATIVE STRESS 24 352 2.468e-12 1.007e-10
115 REGULATION OF LEUKOCYTE DIFFERENTIATION 20 232 2.555e-12 1.025e-10
116 POSITIVE REGULATION OF CELL DEATH 31 605 2.545e-12 1.025e-10
117 SENSORY ORGAN DEVELOPMENT 28 493 2.809e-12 1.117e-10
118 ORGAN FORMATION 10 34 3.14e-12 1.238e-10
119 ANGIOGENESIS 22 293 3.167e-12 1.238e-10
120 REGULATION OF KINASE ACTIVITY 35 776 3.29e-12 1.276e-10
121 CELL DEATH 40 1001 3.488e-12 1.341e-10
122 SEX DIFFERENTIATION 21 266 3.875e-12 1.478e-10
123 RHYTHMIC PROCESS 22 298 4.433e-12 1.677e-10
124 DIGESTIVE TRACT MORPHOGENESIS 11 48 5.178e-12 1.943e-10
125 MYELOID CELL DIFFERENTIATION 18 189 6.183e-12 2.302e-10
126 RESPONSE TO GROWTH FACTOR 27 475 6.96e-12 2.57e-10
127 RESPONSE TO ESTROGEN 19 218 7.585e-12 2.779e-10
128 NEGATIVE REGULATION OF MOLECULAR FUNCTION 41 1079 8.828e-12 3.209e-10
129 ENDOCRINE SYSTEM DEVELOPMENT 15 123 1.062e-11 3.831e-10
130 AXIS ELONGATION 9 27 1.089e-11 3.897e-10
131 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 41 1087 1.113e-11 3.954e-10
132 REGULATION OF TRANSFERASE ACTIVITY 38 946 1.126e-11 3.968e-10
133 NEURON DEVELOPMENT 32 687 1.345e-11 4.706e-10
134 PATTERN SPECIFICATION PROCESS 25 418 1.48e-11 5.138e-10
135 CELLULAR RESPONSE TO STRESS 50 1565 1.822e-11 6.28e-10
136 POSITIVE REGULATION OF MOLECULAR FUNCTION 54 1791 2.13e-11 7.289e-10
137 REGULATION OF STEM CELL PROLIFERATION 13 88 2.201e-11 7.475e-10
138 REGULATION OF MAPK CASCADE 31 660 2.351e-11 7.926e-10
139 CELL MOTILITY 35 835 2.545e-11 8.458e-10
140 LOCALIZATION OF CELL 35 835 2.545e-11 8.458e-10
141 REGULATION OF NERVOUS SYSTEM DEVELOPMENT 33 750 2.833e-11 9.348e-10
142 POSITIVE REGULATION OF CELL COMMUNICATION 49 1532 2.93e-11 9.6e-10
143 MESONEPHROS DEVELOPMENT 13 90 2.953e-11 9.607e-10
144 NEURON PROJECTION DEVELOPMENT 28 545 3.004e-11 9.706e-10
145 MUSCLE CELL DIFFERENTIATION 19 237 3.278e-11 1.052e-09
146 RESPONSE TO KETONE 17 182 3.32e-11 1.058e-09
147 POSITIVE REGULATION OF GROWTH 19 238 3.527e-11 1.116e-09
148 RESPONSE TO METAL ION 22 333 3.917e-11 1.231e-09
149 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 41 1135 4.262e-11 1.331e-09
150 NEPHRON EPITHELIUM DEVELOPMENT 13 93 4.525e-11 1.404e-09
151 RESPONSE TO NITROGEN COMPOUND 35 859 5.542e-11 1.696e-09
152 NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY 16 162 5.515e-11 1.696e-09
153 REPRODUCTION 44 1297 5.653e-11 1.719e-09
154 CANONICAL WNT SIGNALING PATHWAY 13 95 5.963e-11 1.8e-09
155 NEGATIVE REGULATION OF CELL PROLIFERATION 30 643 5.995e-11 1.8e-09
156 STEM CELL PROLIFERATION 11 60 6.966e-11 2.078e-09
157 GLAND MORPHOGENESIS 13 97 7.806e-11 2.314e-09
158 NEGATIVE REGULATION OF WNT SIGNALING PATHWAY 17 197 1.166e-10 3.433e-09
159 TELENCEPHALON DEVELOPMENT 18 228 1.417e-10 4.148e-09
160 KIDNEY MORPHOGENESIS 12 82 1.479e-10 4.302e-09
161 REGULATION OF MUSCLE TISSUE DEVELOPMENT 13 103 1.688e-10 4.848e-09
162 REGULATION OF MUSCLE ORGAN DEVELOPMENT 13 103 1.688e-10 4.848e-09
163 WOUND HEALING 25 470 1.796e-10 5.097e-09
164 PROTEIN PHOSPHORYLATION 36 944 1.788e-10 5.097e-09
165 REGULATION OF IMMUNE SYSTEM PROCESS 45 1403 2.047e-10 5.772e-09
166 AGING 19 264 2.099e-10 5.884e-09
167 POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 24 437 2.229e-10 6.211e-09
168 REGULATION OF NEURON DIFFERENTIATION 27 554 2.259e-10 6.257e-09
169 REGULATION OF CELLULAR COMPONENT MOVEMENT 32 771 2.563e-10 7.058e-09
170 REGULATION OF CELL PROJECTION ORGANIZATION 27 558 2.649e-10 7.251e-09
171 REGULATION OF MYELOID CELL DIFFERENTIATION 16 183 3.437e-10 9.352e-09
172 POSITIVE REGULATION OF NEURON DIFFERENTIATION 20 306 3.807e-10 1.03e-08
173 BRANCH ELONGATION OF AN EPITHELIUM 7 17 4.028e-10 1.083e-08
174 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 49 1656 4.348e-10 1.156e-08
175 RESPONSE TO ABIOTIC STIMULUS 37 1024 4.354e-10 1.156e-08
176 COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION 13 111 4.371e-10 1.156e-08
177 DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS 17 216 4.913e-10 1.292e-08
178 REGIONALIZATION 20 311 5.06e-10 1.323e-08
179 REGULATION OF STEM CELL DIFFERENTIATION 13 113 5.477e-10 1.424e-08
180 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 37 1036 6.007e-10 1.536e-08
181 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 37 1036 6.007e-10 1.536e-08
182 MESENCHYME DEVELOPMENT 16 190 5.992e-10 1.536e-08
183 POSITIVE REGULATION OF HEMOPOIESIS 15 163 6.076e-10 1.545e-08
184 NEGATIVE REGULATION OF PHOSPHORYLATION 23 422 6.279e-10 1.588e-08
185 REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION 11 73 6.352e-10 1.598e-08
186 MAMMARY GLAND DUCT MORPHOGENESIS 8 28 6.443e-10 1.612e-08
187 RESPONSE TO CYTOKINE 30 714 7.382e-10 1.837e-08
188 REGULATION OF EPITHELIAL CELL PROLIFERATION 19 285 7.652e-10 1.892e-08
189 CARDIAC MUSCLE TISSUE DEVELOPMENT 14 140 7.687e-10 1.892e-08
190 REGULATION OF EPITHELIAL CELL MIGRATION 15 166 7.847e-10 1.922e-08
191 POSITIVE REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT 8 29 8.811e-10 2.135e-08
192 RESPONSE TO MOLECULE OF BACTERIAL ORIGIN 20 321 8.792e-10 2.135e-08
193 MESODERM DEVELOPMENT 13 118 9.438e-10 2.275e-08
194 POSITIVE REGULATION OF MAPK CASCADE 24 470 9.637e-10 2.3e-08
195 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 24 470 9.637e-10 2.3e-08
196 EYE DEVELOPMENT 20 326 1.15e-09 2.73e-08
197 RENAL TUBULE DEVELOPMENT 11 78 1.321e-09 3.12e-08
198 NEURON PROJECTION MORPHOGENESIS 22 402 1.401e-09 3.291e-08
199 LIMBIC SYSTEM DEVELOPMENT 12 100 1.566e-09 3.662e-08
200 POSITIVE REGULATION OF CELL CYCLE 20 332 1.577e-09 3.668e-08
201 POSITIVE REGULATION OF KINASE ACTIVITY 24 482 1.59e-09 3.68e-08
202 LUNG MORPHOGENESIS 9 45 1.723e-09 3.968e-08
203 CELL ACTIVATION 26 568 1.879e-09 4.308e-08
204 EMBRYONIC HEART TUBE MORPHOGENESIS 10 62 1.949e-09 4.445e-08
205 METANEPHROS DEVELOPMENT 11 81 1.998e-09 4.535e-08
206 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 20 337 2.04e-09 4.607e-08
207 REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 16 207 2.102e-09 4.725e-08
208 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 27 616 2.285e-09 5.064e-08
209 POSITIVE REGULATION OF WNT SIGNALING PATHWAY 14 152 2.276e-09 5.064e-08
210 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 27 616 2.285e-09 5.064e-08
211 POSITIVE REGULATION OF CATALYTIC ACTIVITY 45 1518 2.485e-09 5.479e-08
212 REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT 9 48 3.165e-09 6.947e-08
213 CELLULAR RESPONSE TO INORGANIC SUBSTANCE 14 156 3.197e-09 6.984e-08
214 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 25 541 3.252e-09 7.039e-08
215 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 25 541 3.252e-09 7.039e-08
216 CELLULAR RESPONSE TO OXIDATIVE STRESS 15 184 3.276e-09 7.056e-08
217 CARDIAC SEPTUM MORPHOGENESIS 9 49 3.839e-09 8.232e-08
218 REGULATION OF CELLULAR COMPONENT BIOGENESIS 30 767 3.91e-09 8.346e-08
219 WNT SIGNALING PATHWAY 20 351 4.095e-09 8.701e-08
220 REGULATION OF HYDROLASE ACTIVITY 41 1327 4.496e-09 9.509e-08
221 REGULATION OF BINDING 18 283 4.574e-09 9.63e-08
222 RESPONSE TO REACTIVE OXYGEN SPECIES 15 191 5.465e-09 1.145e-07
223 EPITHELIAL CELL PROLIFERATION 11 89 5.557e-09 1.159e-07
224 REGULATION OF ENDOTHELIAL CELL MIGRATION 12 114 7.159e-09 1.481e-07
225 CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION 14 166 7.163e-09 1.481e-07
226 RESPONSE TO EXTRACELLULAR STIMULUS 22 441 7.66e-09 1.577e-07
227 REGULATION OF RESPONSE TO STRESS 43 1468 8.61e-09 1.765e-07
228 NEGATIVE REGULATION OF LOCOMOTION 17 263 9.796e-09 1.999e-07
229 REGULATION OF NEURON PROJECTION DEVELOPMENT 21 408 9.924e-09 2.016e-07
230 EMBRYONIC HEART TUBE DEVELOPMENT 10 73 1.01e-08 2.034e-07
231 REGULATION OF ORGAN GROWTH 10 73 1.01e-08 2.034e-07
232 REGULATION OF PROTEOLYSIS 28 711 1.171e-08 2.348e-07
233 MYELOID LEUKOCYTE DIFFERENTIATION 11 96 1.251e-08 2.499e-07
234 LEUKOCYTE ACTIVATION 21 414 1.28e-08 2.544e-07
235 RESPONSE TO ESTRADIOL 13 146 1.3e-08 2.574e-07
236 NEGATIVE REGULATION OF CELL DEVELOPMENT 18 303 1.327e-08 2.617e-07
237 NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 12 121 1.414e-08 2.765e-07
238 GLIOGENESIS 14 175 1.412e-08 2.765e-07
239 REGULATION OF CELL ADHESION 26 629 1.537e-08 2.992e-07
240 POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS 31 867 1.707e-08 3.309e-07
241 PROSTATE GLAND DEVELOPMENT 8 41 1.744e-08 3.352e-07
242 PHOSPHORYLATION 38 1228 1.743e-08 3.352e-07
243 NEGATIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS 17 274 1.799e-08 3.444e-07
244 LYMPHOCYTE DIFFERENTIATION 15 209 1.851e-08 3.529e-07
245 RESPONSE TO MECHANICAL STIMULUS 15 210 1.973e-08 3.747e-07
246 MUSCLE ORGAN DEVELOPMENT 17 277 2.112e-08 3.964e-07
247 REGULATION OF MUSCLE CELL DIFFERENTIATION 13 152 2.113e-08 3.964e-07
248 REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 13 152 2.113e-08 3.964e-07
249 INTRACELLULAR SIGNAL TRANSDUCTION 44 1572 2.157e-08 4.025e-07
250 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 31 876 2.163e-08 4.025e-07
251 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 27 689 2.419e-08 4.484e-07
252 CHONDROCYTE DIFFERENTIATION 9 60 2.478e-08 4.576e-07
253 RESPONSE TO DRUG 21 431 2.564e-08 4.716e-07
254 REGULATION OF LIPID METABOLIC PROCESS 17 282 2.747e-08 5.032e-07
255 BONE DEVELOPMENT 13 156 2.885e-08 5.265e-07
256 CARDIAC CHAMBER MORPHOGENESIS 11 104 2.922e-08 5.311e-07
257 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 21 437 3.25e-08 5.865e-07
258 CELLULAR RESPONSE TO STEROID HORMONE STIMULUS 15 218 3.252e-08 5.865e-07
259 NOTOCHORD DEVELOPMENT 6 18 3.403e-08 6.113e-07
260 POSITIVE REGULATION OF LEUKOCYTE DIFFERENTIATION 12 131 3.469e-08 6.209e-07
261 REGULATION OF FAT CELL DIFFERENTIATION 11 106 3.57e-08 6.365e-07
262 REGULATION OF CARTILAGE DEVELOPMENT 9 63 3.852e-08 6.84e-07
263 POSITIVE REGULATION OF PROTEOLYSIS 19 363 3.963e-08 7.011e-07
264 STEM CELL DIFFERENTIATION 14 190 4.011e-08 7.062e-07
265 POSITIVE REGULATION OF OSSIFICATION 10 84 4.022e-08 7.062e-07
266 CELL PROJECTION ORGANIZATION 31 902 4.204e-08 7.354e-07
267 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 19 365 4.323e-08 7.506e-07
268 SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION 20 404 4.312e-08 7.506e-07
269 CARDIAC SEPTUM DEVELOPMENT 10 85 4.513e-08 7.778e-07
270 PALATE DEVELOPMENT 10 85 4.513e-08 7.778e-07
271 RESPONSE TO HYDROGEN PEROXIDE 11 109 4.783e-08 8.211e-07
272 KIDNEY VASCULATURE DEVELOPMENT 6 19 4.926e-08 8.365e-07
273 RENAL SYSTEM VASCULATURE DEVELOPMENT 6 19 4.926e-08 8.365e-07
274 CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION 19 368 4.92e-08 8.365e-07
275 METANEPHRIC NEPHRON DEVELOPMENT 7 32 6.027e-08 1.02e-06
276 REGULATION OF LIPID KINASE ACTIVITY 8 48 6.429e-08 1.084e-06
277 REGULATION OF SMOOTH MUSCLE CELL DIFFERENTIATION 6 20 6.97e-08 1.158e-06
278 OVULATION CYCLE 11 113 6.963e-08 1.158e-06
279 POSITIVE REGULATION OF CELL ADHESION 19 376 6.902e-08 1.158e-06
280 BRANCHING INVOLVED IN MAMMARY GLAND DUCT MORPHOGENESIS 6 20 6.97e-08 1.158e-06
281 CELL PART MORPHOGENESIS 25 633 7.151e-08 1.184e-06
282 POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT 15 232 7.409e-08 1.222e-06
283 SINGLE ORGANISM CELL ADHESION 21 459 7.488e-08 1.231e-06
284 GLOMERULUS DEVELOPMENT 8 49 7.609e-08 1.247e-06
285 POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION 17 303 7.809e-08 1.275e-06
286 REGULATION OF VASCULATURE DEVELOPMENT 15 233 7.839e-08 1.275e-06
287 POSITIVE REGULATION OF LOCOMOTION 20 420 8.134e-08 1.316e-06
288 REGULATION OF CELL CELL ADHESION 19 380 8.147e-08 1.316e-06
289 NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 11 115 8.353e-08 1.345e-06
290 FEMALE SEX DIFFERENTIATION 11 116 9.137e-08 1.466e-06
291 NEGATIVE REGULATION OF GROWTH 15 236 9.271e-08 1.482e-06
292 LUNG EPITHELIUM DEVELOPMENT 7 34 9.448e-08 1.5e-06
293 REGULATION OF MESENCHYMAL CELL PROLIFERATION 7 34 9.448e-08 1.5e-06
294 REGULATION OF CELLULAR PROTEIN LOCALIZATION 23 552 9.52e-08 1.502e-06
295 REGULATION OF CELL MORPHOGENESIS 23 552 9.52e-08 1.502e-06
296 STRIATED MUSCLE CELL DIFFERENTIATION 13 173 9.832e-08 1.546e-06
297 CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT 9 70 9.876e-08 1.547e-06
298 CARDIAC CHAMBER DEVELOPMENT 12 144 9.949e-08 1.553e-06
299 RESPONSE TO TOXIC SUBSTANCE 15 241 1.219e-07 1.897e-06
300 CELLULAR RESPONSE TO CYTOKINE STIMULUS 24 606 1.263e-07 1.959e-06
301 REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS 12 148 1.346e-07 2.08e-06
302 HEART FORMATION 5 12 1.367e-07 2.1e-06
303 MAMMARY GLAND EPITHELIAL CELL PROLIFERATION 5 12 1.367e-07 2.1e-06
304 REGULATION OF OSSIFICATION 13 178 1.373e-07 2.101e-06
305 HIPPOCAMPUS DEVELOPMENT 9 73 1.431e-07 2.184e-06
306 CARDIOCYTE DIFFERENTIATION 10 96 1.459e-07 2.218e-06
307 EMBRYONIC SKELETAL SYSTEM DEVELOPMENT 11 122 1.536e-07 2.329e-06
308 REGULATION OF TRANSPORT 46 1804 1.567e-07 2.367e-06
309 REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 10 97 1.61e-07 2.425e-06
310 RESPONSE TO ACID CHEMICAL 17 319 1.632e-07 2.45e-06
311 REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS 13 181 1.668e-07 2.491e-06
312 T CELL DIFFERENTIATION 11 123 1.671e-07 2.491e-06
313 POSITIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS 10 98 1.775e-07 2.639e-06
314 REGULATION OF CELL ACTIVATION 21 484 1.818e-07 2.694e-06
315 REGULATION OF ORGANELLE ORGANIZATION 35 1178 1.852e-07 2.735e-06
316 REGULATION OF KIDNEY DEVELOPMENT 8 55 1.937e-07 2.852e-06
317 REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 10 99 1.955e-07 2.861e-06
318 REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 10 99 1.955e-07 2.861e-06
319 POSITIVE REGULATION OF ORGAN GROWTH 7 38 2.132e-07 3.11e-06
320 HEMATOPOIETIC STEM CELL PROLIFERATION 5 13 2.202e-07 3.201e-06
321 DIENCEPHALON DEVELOPMENT 9 77 2.286e-07 3.314e-06
322 HEPATICOBILIARY SYSTEM DEVELOPMENT 11 128 2.51e-07 3.627e-06
323 GLANDULAR EPITHELIAL CELL DIFFERENTIATION 7 39 2.574e-07 3.708e-06
324 TUBE FORMATION 11 129 2.716e-07 3.901e-06
325 POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION 10 103 2.846e-07 4.074e-06
326 TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY 21 498 2.911e-07 4.155e-06
327 EPITHELIAL TUBE BRANCHING INVOLVED IN LUNG MORPHOGENESIS 6 25 3.037e-07 4.321e-06
328 NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 25 684 3.089e-07 4.383e-06
329 OUTFLOW TRACT SEPTUM MORPHOGENESIS 5 14 3.393e-07 4.769e-06
330 SPECIFICATION OF ORGAN IDENTITY 5 14 3.393e-07 4.769e-06
331 VASCULOGENESIS 8 59 3.392e-07 4.769e-06
332 POSITIVE REGULATION OF CELL DIVISION 11 132 3.43e-07 4.793e-06
333 REGULATION OF LYMPHOCYTE DIFFERENTIATION 11 132 3.43e-07 4.793e-06
334 NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 15 262 3.585e-07 4.994e-06
335 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 12 162 3.604e-07 5.006e-06
336 NEGATIVE REGULATION OF FAT CELL DIFFERENTIATION 7 41 3.69e-07 5.079e-06
337 POSITIVE REGULATION OF KIDNEY DEVELOPMENT 7 41 3.69e-07 5.079e-06
338 LUNG ALVEOLUS DEVELOPMENT 7 41 3.69e-07 5.079e-06
339 POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS 15 263 3.764e-07 5.166e-06
340 PEPTIDYL AMINO ACID MODIFICATION 28 841 3.843e-07 5.26e-06
341 POSITIVE REGULATION OF SKELETAL MUSCLE TISSUE DEVELOPMENT 6 26 3.91e-07 5.335e-06
342 EAR DEVELOPMENT 13 195 3.944e-07 5.366e-06
343 MORPHOGENESIS OF EMBRYONIC EPITHELIUM 11 134 3.993e-07 5.401e-06
344 MESENCHYMAL CELL DIFFERENTIATION 11 134 3.993e-07 5.401e-06
345 LYMPHOCYTE ACTIVATION 17 342 4.357e-07 5.877e-06
346 PITUITARY GLAND DEVELOPMENT 7 42 4.385e-07 5.897e-06
347 REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 10 108 4.445e-07 5.96e-06
348 GLIAL CELL DIFFERENTIATION 11 136 4.637e-07 6.2e-06
349 FOREBRAIN CELL MIGRATION 8 62 5.023e-07 6.697e-06
350 POSITIVE REGULATION OF HYDROLASE ACTIVITY 29 905 5.139e-07 6.832e-06
351 BEHAVIOR 21 516 5.199e-07 6.892e-06
352 REGULATION OF PROTEIN BINDING 12 168 5.332e-07 7.048e-06
353 REGULATION OF CYTOKINE PRODUCTION 22 563 5.46e-07 7.197e-06
354 REGULATION OF CELL DIVISION 15 272 5.775e-07 7.59e-06
355 VENTRICULAR SEPTUM MORPHOGENESIS 6 28 6.277e-07 8.228e-06
356 REGULATION OF ACTIN FILAMENT BASED PROCESS 16 312 6.363e-07 8.317e-06
357 REGULATION OF ERK1 AND ERK2 CASCADE 14 238 6.418e-07 8.365e-06
358 REGULATION OF PROTEIN CATABOLIC PROCESS 18 393 6.534e-07 8.492e-06
359 REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION 6 29 7.84e-07 1.013e-05
360 REGULATION OF ORGAN MORPHOGENESIS 14 242 7.837e-07 1.013e-05
361 MESODERM MORPHOGENESIS 8 66 8.205e-07 1.055e-05
362 LENS DEVELOPMENT IN CAMERA TYPE EYE 8 66 8.205e-07 1.055e-05
363 POSITIVE REGULATION OF CELL CELL ADHESION 14 243 8.233e-07 1.055e-05
364 REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 8 67 9.227e-07 1.179e-05
365 SPECIFICATION OF SYMMETRY 10 117 9.365e-07 1.194e-05
366 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 27 829 9.641e-07 1.226e-05
367 REGULATION OF HOMEOSTATIC PROCESS 19 447 9.742e-07 1.235e-05
368 EMBRYONIC DIGESTIVE TRACT MORPHOGENESIS 5 17 1.02e-06 1.289e-05
369 MALE SEX DIFFERENTIATION 11 148 1.08e-06 1.361e-05
370 REGULATION OF METAL ION TRANSPORT 16 325 1.09e-06 1.371e-05
371 OSSIFICATION 14 251 1.211e-06 1.518e-05
372 REGULATION OF CELLULAR LOCALIZATION 35 1277 1.22e-06 1.526e-05
373 APOPTOTIC SIGNALING PATHWAY 15 289 1.237e-06 1.54e-05
374 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 15 289 1.237e-06 1.54e-05
375 REGULATION OF ION TRANSPORT 22 592 1.258e-06 1.561e-05
376 HOMEOSTATIC PROCESS 36 1337 1.272e-06 1.574e-05
377 REGULATION OF PROTEIN LOCALIZATION 29 950 1.369e-06 1.69e-05
378 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 17 372 1.391e-06 1.712e-05
379 NEGATIVE REGULATION OF TRANSPORT 19 458 1.397e-06 1.713e-05
380 KIDNEY MESENCHYME DEVELOPMENT 5 18 1.399e-06 1.713e-05
381 CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN CELL CELL SIGNALING 8 71 1.447e-06 1.768e-05
382 LEUKOCYTE CELL CELL ADHESION 14 255 1.46e-06 1.778e-05
383 REGULATION OF SKELETAL MUSCLE TISSUE DEVELOPMENT 7 50 1.503e-06 1.816e-05
384 POSITIVE REGULATION OF STEM CELL DIFFERENTIATION 7 50 1.503e-06 1.816e-05
385 PALLIUM DEVELOPMENT 11 153 1.499e-06 1.816e-05
386 EPITHELIAL CELL DEVELOPMENT 12 186 1.572e-06 1.895e-05
387 AMEBOIDAL TYPE CELL MIGRATION 11 154 1.599e-06 1.922e-05
388 EMBRYONIC DIGESTIVE TRACT DEVELOPMENT 6 33 1.76e-06 2.11e-05
389 POSITIVE REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION 5 19 1.881e-06 2.25e-05
390 EXTRINSIC APOPTOTIC SIGNALING PATHWAY 9 99 1.975e-06 2.356e-05
391 CARDIAC MUSCLE CELL DIFFERENTIATION 8 74 1.991e-06 2.369e-05
392 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 46 1977 2.07e-06 2.457e-05
393 CD4 POSITIVE ALPHA BETA T CELL ACTIVATION 6 34 2.116e-06 2.506e-05
394 SINGLE ORGANISM BEHAVIOR 17 384 2.14e-06 2.528e-05
395 POSITIVE REGULATION OF PHOSPHOLIPASE ACTIVITY 7 53 2.253e-06 2.633e-05
396 REGULATION OF MORPHOGENESIS OF A BRANCHING STRUCTURE 7 53 2.253e-06 2.633e-05
397 MESONEPHRIC TUBULE MORPHOGENESIS 7 53 2.253e-06 2.633e-05
398 SKELETAL MUSCLE CELL DIFFERENTIATION 7 53 2.253e-06 2.633e-05
399 DEVELOPMENTAL MATURATION 12 193 2.315e-06 2.699e-05
400 REGENERATION 11 161 2.471e-06 2.875e-05
401 TRACHEA DEVELOPMENT 5 20 2.485e-06 2.883e-05
402 REGULATION OF PROTEIN TARGETING 15 307 2.613e-06 3.025e-05
403 REGULATION OF SODIUM ION TRANSPORT 8 77 2.7e-06 3.117e-05
404 CELLULAR RESPONSE TO BIOTIC STIMULUS 11 163 2.787e-06 3.21e-05
405 CRANIAL SKELETAL SYSTEM DEVELOPMENT 7 55 2.909e-06 3.342e-05
406 RESPONSE TO BACTERIUM 20 528 2.937e-06 3.366e-05
407 CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES 9 104 2.984e-06 3.411e-05
408 CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT 6 36 3.007e-06 3.43e-05
409 REGULATION OF TRANSPORTER ACTIVITY 12 198 3.02e-06 3.436e-05
410 POSITIVE REGULATION OF CELL ACTIVATION 15 311 3.062e-06 3.476e-05
411 POSITIVE REGULATION OF CATABOLIC PROCESS 17 395 3.129e-06 3.542e-05
412 REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 8 79 3.282e-06 3.698e-05
413 BONE MORPHOGENESIS 8 79 3.282e-06 3.698e-05
414 NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 12 200 3.351e-06 3.767e-05
415 RESPONSE TO BIOTIC STIMULUS 27 886 3.375e-06 3.784e-05
416 SKELETAL SYSTEM MORPHOGENESIS 12 201 3.529e-06 3.947e-05
417 NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION 6 37 3.555e-06 3.967e-05
418 POSITIVE REGULATION OF LYMPHOCYTE DIFFERENTIATION 8 80 3.611e-06 4.02e-05
419 REGULATION OF T CELL DIFFERENTIATION 9 107 3.781e-06 4.198e-05
420 SENSORY ORGAN MORPHOGENESIS 13 239 3.86e-06 4.276e-05
421 SKELETAL MUSCLE ORGAN DEVELOPMENT 10 137 3.949e-06 4.364e-05
422 CHROMATIN MODIFICATION 20 539 4.002e-06 4.412e-05
423 BONE CELL DEVELOPMENT 5 22 4.143e-06 4.557e-05
424 REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS 6 38 4.182e-06 4.59e-05
425 NEURON PROJECTION GUIDANCE 12 205 4.324e-06 4.734e-05
426 POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS 17 406 4.512e-06 4.928e-05
427 REGULATION OF APOPTOTIC SIGNALING PATHWAY 16 363 4.543e-06 4.95e-05
428 POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE 11 172 4.688e-06 5.097e-05
429 FORMATION OF PRIMARY GERM LAYER 9 110 4.754e-06 5.156e-05
430 POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION 8 84 5.223e-06 5.636e-05
431 HISTONE METHYLATION 8 84 5.223e-06 5.636e-05
432 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS 5 23 5.244e-06 5.636e-05
433 POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS 5 23 5.244e-06 5.636e-05
434 REGULATION OF CYTOSKELETON ORGANIZATION 19 502 5.304e-06 5.687e-05
435 POSITIVE REGULATION OF CELL CYCLE PROCESS 13 247 5.527e-06 5.898e-05
436 REGULATION OF OSTEOBLAST DIFFERENTIATION 9 112 5.515e-06 5.898e-05
437 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 6 40 5.705e-06 6.061e-05
438 ENDOCRINE PANCREAS DEVELOPMENT 6 40 5.705e-06 6.061e-05
439 NEGATIVE REGULATION OF CYTOKINE PRODUCTION 12 211 5.812e-06 6.16e-05
440 EMBRYONIC DIGIT MORPHOGENESIS 7 61 5.901e-06 6.226e-05
441 POSITIVE REGULATION OF STEM CELL PROLIFERATION 7 61 5.901e-06 6.226e-05
442 NEGATIVE REGULATION OF CELL PROJECTION ORGANIZATION 10 144 6.166e-06 6.491e-05
443 NEGATIVE REGULATION OF KINASE ACTIVITY 13 250 6.299e-06 6.617e-05
444 REGULATION OF EMBRYONIC DEVELOPMENT 9 114 6.38e-06 6.686e-05
445 NEGATIVE REGULATION OF MAPK CASCADE 10 145 6.558e-06 6.857e-05
446 REGULATION OF SMOOTHENED SIGNALING PATHWAY 7 62 6.588e-06 6.873e-05
447 REGULATION OF CELL CYCLE PROCESS 20 558 6.691e-06 6.965e-05
448 BIOLOGICAL ADHESION 29 1032 6.894e-06 7.16e-05
449 TRACHEA MORPHOGENESIS 4 12 7.579e-06 7.854e-05
450 NEGATIVE REGULATION OF GTPASE ACTIVITY 6 42 7.65e-06 7.893e-05
451 REGULATION OF HEART GROWTH 6 42 7.65e-06 7.893e-05
452 CHROMATIN ORGANIZATION 22 663 7.772e-06 8e-05
453 NEGATIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 9 117 7.892e-06 8.107e-05
454 SEGMENTATION 8 89 8.059e-06 8.259e-05
455 FOREBRAIN REGIONALIZATION 5 25 8.128e-06 8.312e-05
456 REGULATION OF PHOSPHOLIPASE ACTIVITY 7 64 8.163e-06 8.329e-05
457 NEURAL TUBE DEVELOPMENT 10 149 8.347e-06 8.49e-05
458 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 16 381 8.357e-06 8.49e-05
459 CELL FATE DETERMINATION 6 43 8.807e-06 8.928e-05
460 POSITIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY 9 119 9.063e-06 9.167e-05
461 POSITIVE REGULATION OF TRANSPORT 27 936 9.201e-06 9.287e-05
462 REGULATION OF GTPASE ACTIVITY 22 673 9.821e-06 9.892e-05
463 NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 7 66 1.004e-05 9.98e-05
464 REGULATION OF MEMBRANE POTENTIAL 15 343 9.97e-06 9.98e-05
465 FOREBRAIN GENERATION OF NEURONS 7 66 1.004e-05 9.98e-05
466 NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 7 66 1.004e-05 9.98e-05
467 POSITIVE REGULATION OF LIPASE ACTIVITY 7 66 1.004e-05 9.98e-05
468 REGULATION OF CELL FATE COMMITMENT 5 26 9.97e-06 9.98e-05
469 MYELOID CELL DEVELOPMENT 6 44 1.01e-05 1e-04
470 BRANCHING INVOLVED IN URETERIC BUD MORPHOGENESIS 6 44 1.01e-05 1e-04
471 TRANSCRIPTION INITIATION FROM RNA POLYMERASE II PROMOTER 10 153 1.054e-05 0.0001042
472 POSITIVE REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION 4 13 1.085e-05 0.000107
473 POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION 7 67 1.11e-05 0.0001092
474 POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 10 154 1.116e-05 0.0001096
475 REGULATION OF CATABOLIC PROCESS 23 731 1.132e-05 0.0001109
476 ALPHA BETA T CELL DIFFERENTIATION 6 45 1.154e-05 0.0001124
477 REGULATION OF CELL GROWTH 16 391 1.154e-05 0.0001124
478 ENDOCHONDRAL BONE MORPHOGENESIS 6 45 1.154e-05 0.0001124
479 GASTRULATION 10 155 1.182e-05 0.0001148
480 POSITIVE REGULATION OF HEART GROWTH 5 27 1.212e-05 0.000117
481 REGULATION OF CATENIN IMPORT INTO NUCLEUS 5 27 1.212e-05 0.000117
482 CENTRAL NERVOUS SYSTEM NEURON AXONOGENESIS 5 27 1.212e-05 0.000117
483 ORGAN GROWTH 7 68 1.226e-05 0.0001181
484 REGULATION OF HOMOTYPIC CELL CELL ADHESION 14 307 1.24e-05 0.0001192
485 NEGATIVE REGULATION OF RESPONSE TO WOUNDING 10 156 1.25e-05 0.0001199
486 NEGATIVE REGULATION OF NEURON DIFFERENTIATION 11 191 1.27e-05 0.0001216
487 EMBRYONIC CRANIAL SKELETON MORPHOGENESIS 6 46 1.315e-05 0.0001256
488 POSITIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 11 192 1.334e-05 0.0001272
489 POSITIVE REGULATION OF AXONOGENESIS 7 69 1.351e-05 0.0001285
490 IN UTERO EMBRYONIC DEVELOPMENT 14 311 1.434e-05 0.0001356
491 RESPONSE TO OXYGEN LEVELS 14 311 1.434e-05 0.0001356
492 HEMOSTASIS 14 311 1.434e-05 0.0001356
493 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 9 126 1.44e-05 0.0001359
494 METANEPHRIC MESENCHYME DEVELOPMENT 4 14 1.505e-05 0.0001418
495 POSITIVE REGULATION OF BINDING 9 127 1.535e-05 0.0001443
496 NEGATIVE REGULATION OF HEMOPOIESIS 9 128 1.635e-05 0.0001534
497 REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 13 274 1.678e-05 0.0001571
498 COLUMNAR CUBOIDAL EPITHELIAL CELL DEVELOPMENT 6 48 1.69e-05 0.0001579
499 T CELL DIFFERENTIATION INVOLVED IN IMMUNE RESPONSE 5 29 1.75e-05 0.0001632
500 CYTOKINE MEDIATED SIGNALING PATHWAY 17 452 1.824e-05 0.0001698
501 REGULATION OF MAP KINASE ACTIVITY 14 319 1.903e-05 0.0001767
502 CELLULAR RESPONSE TO CALCIUM ION 6 49 1.908e-05 0.0001769
503 PANCREAS DEVELOPMENT 7 73 1.963e-05 0.0001812
504 REGULATION OF PLASMA MEMBRANE ORGANIZATION 7 73 1.963e-05 0.0001812
505 MUSCLE CELL FATE COMMITMENT 4 15 2.035e-05 0.0001875
506 REGULATION OF ION HOMEOSTASIS 11 201 2.046e-05 0.0001882
507 MAINTENANCE OF CELL NUMBER 9 132 2.092e-05 0.000192
508 CELLULAR RESPONSE TO NITROGEN COMPOUND 18 505 2.112e-05 0.0001934
509 CIRCULATORY SYSTEM PROCESS 15 366 2.137e-05 0.0001954
510 DNA TEMPLATED TRANSCRIPTION INITIATION 11 202 2.143e-05 0.0001955
511 PEPTIDYL LYSINE METHYLATION 7 74 2.147e-05 0.0001955
512 REGULATION OF BODY FLUID LEVELS 18 506 2.168e-05 0.000197
513 NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 8 102 2.204e-05 0.0001999
514 POSITIVE REGULATION OF VASCULATURE DEVELOPMENT 9 133 2.222e-05 0.0002011
515 REGULATION OF RESPONSE TO WOUNDING 16 413 2.258e-05 0.000204
516 CELL DIVISION 17 460 2.28e-05 0.0002056
517 CELL CELL ADHESION 20 608 2.317e-05 0.0002085
518 REGULATION OF AXONOGENESIS 10 168 2.38e-05 0.0002138
519 POSITIVE REGULATION OF CYTOKINE PRODUCTION 15 370 2.424e-05 0.0002174
520 MULTICELLULAR ORGANISM REPRODUCTION 23 768 2.471e-05 0.0002211
521 NEGATIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 9 135 2.502e-05 0.0002229
522 APPENDAGE DEVELOPMENT 10 169 2.505e-05 0.0002229
523 LIMB DEVELOPMENT 10 169 2.505e-05 0.0002229
524 TAXIS 17 464 2.545e-05 0.000226
525 GLIAL CELL DEVELOPMENT 7 76 2.559e-05 0.0002268
526 EYE MORPHOGENESIS 9 136 2.653e-05 0.0002347
527 NEGATIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY 4 16 2.688e-05 0.0002365
528 PARAXIAL MESODERM DEVELOPMENT 4 16 2.688e-05 0.0002365
529 POSITIVE REGULATION OF MAP KINASE ACTIVITY 11 207 2.686e-05 0.0002365
530 REGULATION OF CATION TRANSMEMBRANE TRANSPORT 11 208 2.808e-05 0.0002466
531 REGULATION OF PROTEIN COMPLEX ASSEMBLY 15 375 2.831e-05 0.0002481
532 POSITIVE REGULATION OF LIPID KINASE ACTIVITY 5 32 2.887e-05 0.000252
533 REGULATION OF ORGAN FORMATION 5 32 2.887e-05 0.000252
534 CARDIAC VENTRICLE DEVELOPMENT 8 106 2.915e-05 0.000254
535 RESPONSE TO RETINOIC ACID 8 107 3.12e-05 0.0002714
536 REGULATION OF TRANSMEMBRANE TRANSPORT 16 426 3.284e-05 0.000285
537 COGNITION 12 251 3.298e-05 0.0002857
538 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 19 573 3.348e-05 0.0002895
539 VENTRICULAR SEPTUM DEVELOPMENT 6 54 3.361e-05 0.0002896
540 ALPHA BETA T CELL ACTIVATION 6 54 3.361e-05 0.0002896
541 POSITIVE REGULATION OF EMBRYONIC DEVELOPMENT 5 33 3.371e-05 0.0002899
542 CELLULAR RESPONSE TO ACID CHEMICAL 10 175 3.378e-05 0.00029
543 CHROMOSOME ORGANIZATION 27 1009 3.455e-05 0.000296
544 NEGATIVE REGULATION OF STEM CELL PROLIFERATION 4 17 3.484e-05 0.0002975
545 DORSAL VENTRAL NEURAL TUBE PATTERNING 4 17 3.484e-05 0.0002975
546 MULTI MULTICELLULAR ORGANISM PROCESS 11 213 3.493e-05 0.0002977
547 EPIDERMIS DEVELOPMENT 12 253 3.563e-05 0.0003031
548 NEGATIVE REGULATION OF MUSCLE CELL DIFFERENTIATION 6 55 3.737e-05 0.0003173
549 FOREBRAIN NEURON DEVELOPMENT 5 34 3.916e-05 0.0003283
550 POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 5 34 3.916e-05 0.0003283
551 RESPONSE TO FLUID SHEAR STRESS 5 34 3.916e-05 0.0003283
552 PROTEIN KINASE B SIGNALING 5 34 3.916e-05 0.0003283
553 POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION 7 81 3.878e-05 0.0003283
554 OLIGODENDROCYTE DEVELOPMENT 5 34 3.916e-05 0.0003283
555 NEURAL TUBE PATTERNING 5 34 3.916e-05 0.0003283
556 EPITHELIAL TO MESENCHYMAL TRANSITION 6 56 4.146e-05 0.0003469
557 NEGATIVE REGULATION OF LEUKOCYTE DIFFERENTIATION 7 82 4.2e-05 0.0003508
558 GLANDULAR EPITHELIAL CELL DEVELOPMENT 4 18 4.44e-05 0.0003702
559 RESPONSE TO MINERALOCORTICOID 5 35 4.526e-05 0.0003767
560 ORGAN REGENERATION 7 83 4.542e-05 0.0003768
561 REGULATION OF LIPASE ACTIVITY 7 83 4.542e-05 0.0003768
562 REGULATION OF CELLULAR RESPONSE TO STRESS 21 691 4.581e-05 0.0003792
563 NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH 7 84 4.908e-05 0.0004056
564 NOTCH SIGNALING PATHWAY 8 114 4.921e-05 0.000406
565 REGULATION OF PROTEIN IMPORT 10 183 4.938e-05 0.0004066
566 REGULATION OF ERYTHROCYTE DIFFERENTIATION 5 36 5.207e-05 0.0004281
567 RESPONSE TO INTERLEUKIN 1 8 115 5.238e-05 0.0004284
568 CELLULAR RESPONSE TO ALCOHOL 8 115 5.238e-05 0.0004284
569 RESPONSE TO CALCIUM ION 8 115 5.238e-05 0.0004284
570 REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION 7 85 5.297e-05 0.0004324
571 POSITIVE REGULATION OF DNA METABOLIC PROCESS 10 185 5.412e-05 0.000441
572 RESPONSE TO MUSCLE STRETCH 4 19 5.574e-05 0.0004502
573 REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION 4 19 5.574e-05 0.0004502
574 LIVER REGENERATION 4 19 5.574e-05 0.0004502
575 ENTEROENDOCRINE CELL DIFFERENTIATION 4 19 5.574e-05 0.0004502
576 ESTROUS CYCLE 4 19 5.574e-05 0.0004502
577 POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 7 86 5.711e-05 0.0004606
578 SYSTEM PROCESS 39 1785 5.842e-05 0.0004703
579 IMMUNE RESPONSE 28 1100 5.894e-05 0.0004737
580 PROTEIN METHYLATION 8 117 5.923e-05 0.0004743
581 PROTEIN ALKYLATION 8 117 5.923e-05 0.0004743
582 CARDIAC MUSCLE CELL ACTION POTENTIAL 5 37 5.966e-05 0.0004761
583 POSITIVE REGULATION OF ALPHA BETA T CELL DIFFERENTIATION 5 37 5.966e-05 0.0004761
584 POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION 6 60 6.154e-05 0.0004887
585 POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION 6 60 6.154e-05 0.0004887
586 OLIGODENDROCYTE DIFFERENTIATION 6 60 6.154e-05 0.0004887
587 POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 11 228 6.475e-05 0.0005133
588 LEUKOCYTE PROLIFERATION 7 88 6.619e-05 0.0005238
589 NEGATIVE REGULATION OF CATION TRANSMEMBRANE TRANSPORT 6 61 6.761e-05 0.0005323
590 REGULATION OF PHOSPHOLIPID METABOLIC PROCESS 6 61 6.761e-05 0.0005323
591 CELLULAR RESPONSE TO HYDROGEN PEROXIDE 6 61 6.761e-05 0.0005323
592 POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT 5 38 6.806e-05 0.000534
593 REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY 5 38 6.806e-05 0.000534
594 PROTEIN AUTOPHOSPHORYLATION 10 192 7.39e-05 0.0005788
595 POSITIVE REGULATION OF NUCLEAR DIVISION 6 62 7.415e-05 0.0005799
596 REGULATION OF PROTEIN KINASE B SIGNALING 8 121 7.516e-05 0.0005868
597 EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 5 39 7.735e-05 0.0006019
598 NEGATIVE REGULATION OF ENDOTHELIAL CELL MIGRATION 5 39 7.735e-05 0.0006019
599 REGULATION OF EPITHELIAL CELL DIFFERENTIATION 8 122 7.966e-05 0.0006188
600 ANTERIOR POSTERIOR PATTERN SPECIFICATION 10 194 8.056e-05 0.0006248
601 DORSAL VENTRAL PATTERN FORMATION 7 91 8.199e-05 0.0006348
602 POSITIVE REGULATION OF MITOTIC CELL CYCLE 8 123 8.438e-05 0.0006512
603 POSITIVE REGULATION OF CIRCADIAN RHYTHM 4 21 8.454e-05 0.0006512
604 NEGATIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT 4 21 8.454e-05 0.0006512
605 HORMONE MEDIATED SIGNALING PATHWAY 9 158 8.565e-05 0.0006588
606 NEGATIVE REGULATION OF TRANSPORTER ACTIVITY 6 64 8.874e-05 0.0006802
607 REGULATION OF PROTEIN ACETYLATION 6 64 8.874e-05 0.0006802
608 REGULATION OF JNK CASCADE 9 159 8.991e-05 0.0006881
609 REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 10 197 9.152e-05 0.0006992
610 EMBRYONIC SKELETAL SYSTEM MORPHOGENESIS 7 93 9.414e-05 0.0007181
611 STEROID HORMONE MEDIATED SIGNALING PATHWAY 8 125 9.451e-05 0.0007197
612 CELLULAR RESPONSE TO RETINOIC ACID 6 65 9.684e-05 0.0007351
613 REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS 6 65 9.684e-05 0.0007351
614 REGULATION OF INTRACELLULAR TRANSPORT 19 621 9.751e-05 0.000739
615 REGULATION OF MEMBRANE DEPOLARIZATION 5 41 9.883e-05 0.0007441
616 NEGATIVE REGULATION OF STRESS ACTIVATED MAPK CASCADE 5 41 9.883e-05 0.0007441
617 NEGATIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 5 41 9.883e-05 0.0007441
618 REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY 5 41 9.883e-05 0.0007441
619 REGULATION OF MITOTIC CELL CYCLE 16 468 9.95e-05 0.000748
620 REGULATION OF WOUND HEALING 8 126 9.994e-05 0.0007488
621 OSTEOBLAST DIFFERENTIATION 8 126 9.994e-05 0.0007488
622 CENTRAL NERVOUS SYSTEM PROJECTION NEURON AXONOGENESIS 4 22 0.0001024 0.000766
623 POSITIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS 5 42 0.0001112 0.0008288
624 POSITIVE REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION 5 42 0.0001112 0.0008288
625 POSITIVE REGULATION OF LIPID METABOLIC PROCESS 8 128 0.0001116 0.0008306
626 REACTIVE OXYGEN SPECIES METABOLIC PROCESS 7 96 0.0001151 0.0008553
627 PROSTATE GLAND MORPHOGENESIS 4 23 0.0001229 0.0009059
628 RESPONSE TO INCREASED OXYGEN LEVELS 4 23 0.0001229 0.0009059
629 ADRENAL GLAND DEVELOPMENT 4 23 0.0001229 0.0009059
630 REGULATION OF METANEPHROS DEVELOPMENT 4 23 0.0001229 0.0009059
631 RESPONSE TO HYPEROXIA 4 23 0.0001229 0.0009059
632 NEGATIVE REGULATION OF STEM CELL DIFFERENTIATION 5 43 0.0001246 0.0009175
633 MACROMOLECULE METHYLATION 10 205 0.0001271 0.0009342
634 POSITIVE REGULATION OF TRANSMEMBRANE TRANSPORT 8 131 0.0001311 0.0009592
635 CELL MATURATION 8 131 0.0001311 0.0009592
636 RESPONSE TO VITAMIN 7 98 0.000131 0.0009592
637 REGULATION OF CYTOPLASMIC TRANSPORT 16 481 0.0001363 0.0009959
638 NEGATIVE REGULATION OF CELL CYCLE 15 433 0.0001422 0.001037
639 REGULATION OF ODONTOGENESIS 4 24 0.0001461 0.001062
640 EPITHELIAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT 4 24 0.0001461 0.001062
641 NEURAL PRECURSOR CELL PROLIFERATION 6 70 0.0001466 0.001064
642 NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 10 209 0.0001489 0.001076
643 REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION 7 100 0.0001487 0.001076
644 POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 7 100 0.0001487 0.001076
645 NEGATIVE REGULATION OF CELL GROWTH 9 170 0.0001496 0.001079
646 NEGATIVE REGULATION OF NEURON DEATH 9 171 0.0001564 0.001127
647 REGULATION OF RESPONSE TO EXTERNAL STIMULUS 24 926 0.0001567 0.001127
648 CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM 11 252 0.0001572 0.001127
649 REGULATION OF NEURON DEATH 11 252 0.0001572 0.001127
650 CAMERA TYPE EYE MORPHOGENESIS 7 101 0.0001583 0.001133
651 RENAL SYSTEM PROCESS 7 102 0.0001683 0.001203
652 RESPONSE TO ETHANOL 8 136 0.0001699 0.001213
653 LENS FIBER CELL DIFFERENTIATION 4 25 0.0001724 0.001217
654 LUNG CELL DIFFERENTIATION 4 25 0.0001724 0.001217
655 DOPAMINE METABOLIC PROCESS 4 25 0.0001724 0.001217
656 CEREBELLAR CORTEX DEVELOPMENT 5 46 0.0001726 0.001217
657 REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 4 25 0.0001724 0.001217
658 REGULATION OF CHONDROCYTE DIFFERENTIATION 5 46 0.0001726 0.001217
659 REGULATION OF ALPHA BETA T CELL DIFFERENTIATION 5 46 0.0001726 0.001217
660 EPITHELIAL CELL APOPTOTIC PROCESS 4 25 0.0001724 0.001217
661 REGULATION OF PEPTIDASE ACTIVITY 14 392 0.0001732 0.001219
662 COVALENT CHROMATIN MODIFICATION 13 345 0.0001754 0.001233
663 ERYTHROCYTE HOMEOSTASIS 6 73 0.000185 0.001297
664 CELLULAR RESPONSE TO KETONE 6 73 0.000185 0.001297
665 HOMEOSTASIS OF NUMBER OF CELLS 9 175 0.0001861 0.001302
666 CELL CELL SIGNALING 21 767 0.0001966 0.001374
667 NEGATIVE REGULATION OF HYDROLASE ACTIVITY 14 397 0.0001974 0.001377
668 REGULATION OF STEROID METABOLIC PROCESS 6 74 0.0001995 0.001389
669 REGULATION OF T CELL DIFFERENTIATION IN THYMUS 4 26 0.0002019 0.001392
670 REGULATION OF THYMOCYTE AGGREGATION 4 26 0.0002019 0.001392
671 NEGATIVE REGULATION OF CARTILAGE DEVELOPMENT 4 26 0.0002019 0.001392
672 NEGATIVE REGULATION OF EMBRYONIC DEVELOPMENT 4 26 0.0002019 0.001392
673 MESODERMAL CELL DIFFERENTIATION 4 26 0.0002019 0.001392
674 RESPONSE TO CORTICOSTERONE 4 26 0.0002019 0.001392
675 ODONTOGENESIS 7 105 0.0002015 0.001392
676 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 13 351 0.0002075 0.001428
677 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 10 218 0.0002096 0.00144
678 REGULATION OF MYOBLAST DIFFERENTIATION 5 48 0.0002117 0.00145
679 REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT 5 48 0.0002117 0.00145
680 FAT CELL DIFFERENTIATION 7 106 0.0002137 0.001462
681 CARDIAC MUSCLE ADAPTATION 3 11 0.0002255 0.001515
682 LOOP OF HENLE DEVELOPMENT 3 11 0.0002255 0.001515
683 CELL DIFFERENTIATION INVOLVED IN METANEPHROS DEVELOPMENT 3 11 0.0002255 0.001515
684 NEGATIVE REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 3 11 0.0002255 0.001515
685 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 10 220 0.0002256 0.001515
686 POSITIVE REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 3 11 0.0002255 0.001515
687 CARDIAC CELL FATE COMMITMENT 3 11 0.0002255 0.001515
688 MUSCLE HYPERTROPHY IN RESPONSE TO STRESS 3 11 0.0002255 0.001515
689 CD4 POSITIVE OR CD8 POSITIVE ALPHA BETA T CELL LINEAGE COMMITMENT 3 11 0.0002255 0.001515
690 PROSTATE GLAND GROWTH 3 11 0.0002255 0.001515
691 OLFACTORY BULB INTERNEURON DEVELOPMENT 3 11 0.0002255 0.001515
692 MITOCHONDRION DISTRIBUTION 3 11 0.0002255 0.001515
693 CARDIAC MUSCLE HYPERTROPHY IN RESPONSE TO STRESS 3 11 0.0002255 0.001515
694 PLATELET ACTIVATION 8 142 0.0002285 0.001531
695 MULTI ORGANISM REPRODUCTIVE PROCESS 23 891 0.0002287 0.001531
696 CELLULAR RESPONSE TO EXTERNAL STIMULUS 11 264 0.0002352 0.001568
697 DEVELOPMENTAL INDUCTION 4 27 0.0002349 0.001568
698 POSITIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION 4 27 0.0002349 0.001568
699 CELLULAR RESPONSE TO OXYGEN LEVELS 8 143 0.0002397 0.001593
700 LOCOMOTORY BEHAVIOR 9 181 0.0002394 0.001593
701 REGULATION OF RESPONSE TO CYTOKINE STIMULUS 8 144 0.0002513 0.001668
702 RESPONSE TO PROGESTERONE 5 50 0.0002571 0.001704
703 PEPTIDYL LYSINE MODIFICATION 12 312 0.0002578 0.001706
704 SYNAPSE ORGANIZATION 8 145 0.0002634 0.001741
705 SOMITE DEVELOPMENT 6 78 0.0002663 0.001758
706 CELL FATE COMMITMENT INVOLVED IN FORMATION OF PRIMARY GERM LAYER 4 28 0.0002717 0.001785
707 REGULATION OF NEUROBLAST PROLIFERATION 4 28 0.0002717 0.001785
708 METANEPHROS MORPHOGENESIS 4 28 0.0002717 0.001785
709 POSITIVE REGULATION OF ALPHA BETA T CELL ACTIVATION 5 51 0.0002824 0.001854
710 PEPTIDYL TYROSINE MODIFICATION 9 186 0.0002929 0.00192
711 ANATOMICAL STRUCTURE REGRESSION 3 12 0.0002981 0.00194
712 NEGATIVE REGULATION OF ANDROGEN RECEPTOR SIGNALING PATHWAY 3 12 0.0002981 0.00194
713 POSITIVE REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS 3 12 0.0002981 0.00194
714 LENS FIBER CELL DEVELOPMENT 3 12 0.0002981 0.00194
715 REGULATION OF SKELETAL MUSCLE CELL PROLIFERATION 3 12 0.0002981 0.00194
716 RESPONSE TO TRANSITION METAL NANOPARTICLE 8 148 0.0003027 0.001967
717 POSITIVE REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION 5 52 0.0003096 0.002009
718 STEM CELL DIVISION 4 29 0.0003123 0.002016
719 REGULATION OF HEART MORPHOGENESIS 4 29 0.0003123 0.002016
720 EMBRYONIC HINDLIMB MORPHOGENESIS 4 29 0.0003123 0.002016
721 NEUROBLAST PROLIFERATION 4 29 0.0003123 0.002016
722 REGULATION OF NITRIC OXIDE BIOSYNTHETIC PROCESS 5 53 0.0003387 0.00218
723 NEGATIVE REGULATION OF EPITHELIAL CELL MIGRATION 5 53 0.0003387 0.00218
724 REGULATION OF IMMUNE RESPONSE 22 858 0.0003442 0.002212
725 SMOOTH MUSCLE CELL DIFFERENTIATION 4 30 0.0003572 0.002283
726 CEREBELLAR CORTEX MORPHOGENESIS 4 30 0.0003572 0.002283
727 NEGATIVE REGULATION OF INTRACELLULAR STEROID HORMONE RECEPTOR SIGNALING PATHWAY 4 30 0.0003572 0.002283
728 RESPONSE TO NUTRIENT 9 191 0.000356 0.002283
729 REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 5 54 0.0003698 0.002361
730 REGULATION OF POTASSIUM ION TRANSPORT 6 83 0.0003733 0.002379
731 ACTIVATION OF PROTEIN KINASE ACTIVITY 11 279 0.0003766 0.002397
732 TYPE B PANCREATIC CELL DEVELOPMENT 3 13 0.0003843 0.002433
733 CELLULAR RESPONSE TO THYROID HORMONE STIMULUS 3 13 0.0003843 0.002433
734 MESENCHYMAL CELL PROLIFERATION 3 13 0.0003843 0.002433
735 REGULATION OF CELL FATE SPECIFICATION 3 13 0.0003843 0.002433
736 REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 11 280 0.0003882 0.002454
737 POSITIVE REGULATION OF ION TRANSPORT 10 236 0.0003944 0.00249
738 NEGATIVE REGULATION OF MYELOID CELL DIFFERENTIATION 6 84 0.0003982 0.002511
739 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 5 55 0.0004031 0.002538
740 MACROPHAGE ACTIVATION 4 31 0.0004064 0.002556
741 MUSCLE SYSTEM PROCESS 11 282 0.0004121 0.002588
742 PROTEIN LOCALIZATION TO NUCLEUS 8 156 0.0004311 0.002703
743 METHYLATION 11 284 0.0004374 0.002739
744 SMAD PROTEIN SIGNAL TRANSDUCTION 5 56 0.0004385 0.002743
745 CHEMICAL HOMEOSTASIS 22 874 0.0004421 0.002761
746 POSITIVE REGULATION OF PROTEIN COMPLEX ASSEMBLY 9 197 0.0004461 0.002783
747 REGULATION OF DEFENSE RESPONSE 20 759 0.0004562 0.002838
748 REGULATION OF DENDRITE DEVELOPMENT 7 120 0.0004562 0.002838
749 NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 32 0.0004604 0.002849
750 POSITIVE REGULATION OF BMP SIGNALING PATHWAY 4 32 0.0004604 0.002849
751 PROXIMAL DISTAL PATTERN FORMATION 4 32 0.0004604 0.002849
752 NEGATIVE REGULATION OF POTASSIUM ION TRANSPORT 4 32 0.0004604 0.002849
753 NEGATIVE REGULATION OF CELL ACTIVATION 8 158 0.0004693 0.0029
754 NEGATIVE REGULATION OF TRANSMEMBRANE TRANSPORT 6 87 0.0004809 0.002964
755 TISSUE REMODELING 6 87 0.0004809 0.002964
756 HISTONE H3 K9 MODIFICATION 3 14 0.000485 0.002977
757 CELL MIGRATION INVOLVED IN GASTRULATION 3 14 0.000485 0.002977
758 RESPONSE TO LAMINAR FLUID SHEAR STRESS 3 14 0.000485 0.002977
759 MYELOID CELL HOMEOSTASIS 6 88 0.0005113 0.00313
760 CELLULAR RESPONSE TO INTERLEUKIN 1 6 88 0.0005113 0.00313
761 NEGATIVE REGULATION OF WOUND HEALING 5 58 0.0005164 0.003149
762 CELLULAR RESPONSE TO CORTICOSTEROID STIMULUS 5 58 0.0005164 0.003149
763 EMBRYONIC PATTERN SPECIFICATION 5 58 0.0005164 0.003149
764 POSITIVE REGULATION OF RESPONSE TO CYTOKINE STIMULUS 4 33 0.0005192 0.003154
765 NEGATIVE REGULATION OF JNK CASCADE 4 33 0.0005192 0.003154
766 RESPONSE TO DEXAMETHASONE 4 33 0.0005192 0.003154
767 INOSITOL LIPID MEDIATED SIGNALING 7 124 0.0005556 0.00337
768 REGULATION OF DNA METABOLIC PROCESS 12 340 0.0005574 0.003377
769 AXIS SPECIFICATION 6 90 0.0005764 0.003481
770 REGULATION OF NUCLEAR DIVISION 8 163 0.0005768 0.003481
771 NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY 6 90 0.0005764 0.003481
772 PROTEIN DESTABILIZATION 4 34 0.0005832 0.003511
773 BRAIN MORPHOGENESIS 4 34 0.0005832 0.003511
774 OLFACTORY BULB INTERNEURON DIFFERENTIATION 3 15 0.0006012 0.003573
775 HYALURONAN CATABOLIC PROCESS 3 15 0.0006012 0.003573
776 POSITIVE REGULATION OF STRIATED MUSCLE CONTRACTION 3 15 0.0006012 0.003573
777 REGULATION OF MESODERM DEVELOPMENT 3 15 0.0006012 0.003573
778 REGULATION OF N METHYL D ASPARTATE SELECTIVE GLUTAMATE RECEPTOR ACTIVITY 3 15 0.0006012 0.003573
779 VENTRICULAR CARDIAC MUSCLE CELL ACTION POTENTIAL 3 15 0.0006012 0.003573
780 GRANULOCYTE DIFFERENTIATION 3 15 0.0006012 0.003573
781 T CELL LINEAGE COMMITMENT 3 15 0.0006012 0.003573
782 MEMBRANE REPOLARIZATION 3 15 0.0006012 0.003573
783 RESPONSE TO FOLIC ACID 3 15 0.0006012 0.003573
784 T CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE 5 60 0.0006043 0.003587
785 NEGATIVE REGULATION OF ION TRANSPORT 7 127 0.0006408 0.003798
786 INNER EAR MORPHOGENESIS 6 92 0.0006479 0.003835
787 POSITIVE REGULATION OF HEART CONTRACTION 4 35 0.0006527 0.003844
788 REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT 5 61 0.0006522 0.003844
789 EMBRYONIC CAMERA TYPE EYE DEVELOPMENT 4 35 0.0006527 0.003844
790 RESPONSE TO MONOAMINE 4 35 0.0006527 0.003844
791 REGULATION OF CALCIUM ION TRANSPORT 9 209 0.0006829 0.004017
792 INTRACELLULAR RECEPTOR SIGNALING PATHWAY 8 168 0.0007036 0.004133
793 REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS 3 16 0.0007337 0.004231
794 CARDIAC MYOFIBRIL ASSEMBLY 3 16 0.0007337 0.004231
795 REGULATION OF GRANULOCYTE DIFFERENTIATION 3 16 0.0007337 0.004231
796 NEGATIVE REGULATION OF RESPONSE TO EXTRACELLULAR STIMULUS 4 36 0.0007277 0.004231
797 MEGAKARYOCYTE DEVELOPMENT 3 16 0.0007337 0.004231
798 ACTION POTENTIAL 6 94 0.000726 0.004231
799 OLFACTORY LOBE DEVELOPMENT 4 36 0.0007277 0.004231
800 NEGATIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT 4 36 0.0007277 0.004231
801 NEGATIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS 3 16 0.0007337 0.004231
802 FEMALE GENITALIA DEVELOPMENT 3 16 0.0007337 0.004231
803 POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 36 0.0007277 0.004231
804 MONOCYTE DIFFERENTIATION 3 16 0.0007337 0.004231
805 T CELL SELECTION 4 36 0.0007277 0.004231
806 NEGATIVE REGULATION OF RESPONSE TO NUTRIENT LEVELS 4 36 0.0007277 0.004231
807 POSITIVE CHEMOTAXIS 4 36 0.0007277 0.004231
808 NEUROEPITHELIAL CELL DIFFERENTIATION 5 63 0.0007566 0.004357
809 NEGATIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 6 95 0.0007676 0.004415
810 NEGATIVE REGULATION OF BINDING 7 131 0.0007703 0.004425
811 POSITIVE REGULATION OF IMMUNE RESPONSE 16 563 0.0007717 0.004427
812 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 9 213 0.0007816 0.004479
813 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 8 171 0.0007898 0.00452
814 HINDLIMB MORPHOGENESIS 4 37 0.0008087 0.0046
815 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CELL PERIPHERY 4 37 0.0008087 0.0046
816 MYOBLAST DIFFERENTIATION 4 37 0.0008087 0.0046
817 POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY 7 132 0.0008057 0.0046
818 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE 4 37 0.0008087 0.0046
819 REGULATION OF CARBOHYDRATE METABOLIC PROCESS 8 172 0.0008203 0.004661
820 POSITIVE REGULATION OF CATION TRANSMEMBRANE TRANSPORT 6 97 0.0008565 0.00486
821 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 15 514 0.0008608 0.004878
822 NEGATIVE REGULATION OF AXONOGENESIS 5 65 0.0008728 0.004941
823 CELLULAR RESPONSE TO LITHIUM ION 3 17 0.0008835 0.004971
824 INTESTINAL EPITHELIAL CELL DIFFERENTIATION 3 17 0.0008835 0.004971
825 REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 3 17 0.0008835 0.004971
826 DEFINITIVE HEMOPOIESIS 3 17 0.0008835 0.004971
827 RESPONSE TO MANGANESE ION 3 17 0.0008835 0.004971
828 RESPONSE TO TESTOSTERONE 4 38 0.0008959 0.005022
829 BONE MINERALIZATION 4 38 0.0008959 0.005022
830 MESENCHYME MORPHOGENESIS 4 38 0.0008959 0.005022
831 HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION 6 98 0.0009038 0.005049
832 MYELOID LEUKOCYTE ACTIVATION 6 98 0.0009038 0.005049
833 LYMPHOCYTE ACTIVATION INVOLVED IN IMMUNE RESPONSE 6 98 0.0009038 0.005049
834 CELLULAR RESPONSE TO ABIOTIC STIMULUS 10 263 0.0009117 0.005087
835 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 12 360 0.0009177 0.005114
836 SOMATIC STEM CELL POPULATION MAINTENANCE 5 66 0.0009357 0.005202
837 REGULATION OF MULTICELLULAR ORGANISM GROWTH 5 66 0.0009357 0.005202
838 STRIATED MUSCLE CONTRACTION 6 99 0.0009531 0.005292
839 RESPONSE TO RADIATION 13 413 0.0009594 0.005321
840 REGULATION OF PHOSPHOLIPASE C ACTIVITY 4 39 0.0009894 0.005455
841 REGULATION OF AXON GUIDANCE 4 39 0.0009894 0.005455
842 ASTROCYTE DIFFERENTIATION 4 39 0.0009894 0.005455
843 COCHLEA DEVELOPMENT 4 39 0.0009894 0.005455
844 PLATELET AGGREGATION 4 39 0.0009894 0.005455
845 CIRCADIAN RHYTHM 7 137 0.001002 0.005513
846 POSITIVE REGULATION OF NEURON DEATH 5 67 0.001002 0.005513
847 NEGATIVE REGULATION OF INFLAMMATORY RESPONSE 6 100 0.001004 0.005518
848 POSITIVE REGULATION OF DEFENSE RESPONSE 12 364 0.001009 0.005537
849 REGULATION OF HEART CONTRACTION 9 221 0.001014 0.005556
850 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 7 138 0.001046 0.005726
851 REGULATION OF MITOCHONDRIAL DEPOLARIZATION 3 18 0.001051 0.005728
852 NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR 3 18 0.001051 0.005728
853 REGULATION OF DELAYED RECTIFIER POTASSIUM CHANNEL ACTIVITY 3 18 0.001051 0.005728
854 POST ANAL TAIL MORPHOGENESIS 3 18 0.001051 0.005728
855 REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION 6 101 0.001058 0.005757
856 REGULATION OF ALPHA BETA T CELL ACTIVATION 5 68 0.001072 0.005811
857 POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION 5 68 0.001072 0.005811
858 POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION 5 68 0.001072 0.005811
859 NEGATIVE REGULATION OF CELL ADHESION 9 223 0.00108 0.005849
860 RESPONSE TO ORGANOPHOSPHORUS 7 139 0.001091 0.005875
861 FORELIMB MORPHOGENESIS 4 40 0.00109 0.005875
862 NEGATIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 4 40 0.00109 0.005875
863 CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE 7 139 0.001091 0.005875
864 REGULATION OF ANATOMICAL STRUCTURE SIZE 14 472 0.001092 0.005875
865 HINDBRAIN MORPHOGENESIS 4 40 0.00109 0.005875
866 REGULATION OF CHEMOTAXIS 8 180 0.001101 0.005913
867 REGULATION OF CIRCADIAN RHYTHM 6 103 0.001171 0.006272
868 REGULATION OF CALCIUM ION IMPORT 6 103 0.001171 0.006272
869 STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 6 103 0.001171 0.006272
870 ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY 7 141 0.001185 0.00634
871 CELLULAR RESPONSE TO ESTROGEN STIMULUS 4 41 0.001197 0.006393
872 VENTRICULAR CARDIAC MUSCLE CELL DIFFERENTIATION 3 19 0.001238 0.006553
873 DRUG TRANSMEMBRANE TRANSPORT 3 19 0.001238 0.006553
874 EPIDERMAL CELL DIFFERENTIATION 7 142 0.001235 0.006553
875 PLATELET MORPHOGENESIS 3 19 0.001238 0.006553
876 RESPONSE TO CAMP 6 104 0.001231 0.006553
877 CARTILAGE DEVELOPMENT INVOLVED IN ENDOCHONDRAL BONE MORPHOGENESIS 3 19 0.001238 0.006553
878 GLOMERULAR EPITHELIUM DEVELOPMENT 3 19 0.001238 0.006553
879 POSITIVE REGULATION OF PROTEIN IMPORT 6 104 0.001231 0.006553
880 NEGATIVE REGULATION OF INTRACELLULAR TRANSPORT 7 143 0.001286 0.006801
881 NEGATIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 4 42 0.001311 0.006893
882 CATECHOLAMINE METABOLIC PROCESS 4 42 0.001311 0.006893
883 PROTEIN LOCALIZATION 35 1805 0.001311 0.006893
884 CATECHOL CONTAINING COMPOUND METABOLIC PROCESS 4 42 0.001311 0.006893
885 GENITALIA DEVELOPMENT 4 42 0.001311 0.006893
886 RESPONSE TO TRANSFORMING GROWTH FACTOR BETA 7 144 0.001339 0.007033
887 SMOOTHENED SIGNALING PATHWAY 5 72 0.001386 0.007273
888 EMBRYONIC HEMOPOIESIS 3 20 0.001444 0.007484
889 INTERMEDIATE FILAMENT ORGANIZATION 3 20 0.001444 0.007484
890 HYPEROSMOTIC RESPONSE 3 20 0.001444 0.007484
891 BONE GROWTH 3 20 0.001444 0.007484
892 NEGATIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 4 43 0.001433 0.007484
893 GENETIC IMPRINTING 3 20 0.001444 0.007484
894 MEGAKARYOCYTE DIFFERENTIATION 3 20 0.001444 0.007484
895 CEREBRAL CORTEX CELL MIGRATION 4 43 0.001433 0.007484
896 REGULATION OF TRANSCRIPTION INVOLVED IN CELL FATE COMMITMENT 3 20 0.001444 0.007484
897 SERTOLI CELL DIFFERENTIATION 3 20 0.001444 0.007484
898 RESPONSE TO LEPTIN 3 20 0.001444 0.007484
899 NEGATIVE REGULATION OF PROTEOLYSIS 11 329 0.001453 0.007521
900 RESPONSE TO TUMOR NECROSIS FACTOR 9 233 0.001464 0.007569
901 POSITIVE REGULATION OF PROTEIN BINDING 5 73 0.001475 0.007616
902 TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 8 190 0.001553 0.008011
903 NEGATIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 4 44 0.001562 0.00804
904 NEGATIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION 4 44 0.001562 0.00804
905 PEPTIDYL SERINE MODIFICATION 7 148 0.001568 0.008044
906 POSITIVE REGULATION OF CELL GROWTH 7 148 0.001568 0.008044
907 ACTIN MEDIATED CELL CONTRACTION 5 74 0.001567 0.008044
908 INTERSPECIES INTERACTION BETWEEN ORGANISMS 17 662 0.001603 0.008203
909 SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM 17 662 0.001603 0.008203
910 NEURON MIGRATION 6 110 0.001643 0.008401
911 METANEPHRIC NEPHRON MORPHOGENESIS 3 21 0.001671 0.008478
912 ARTERY DEVELOPMENT 5 75 0.001664 0.008478
913 REGULATION OF BIOMINERAL TISSUE DEVELOPMENT 5 75 0.001664 0.008478
914 POSITIVE T CELL SELECTION 3 21 0.001671 0.008478
915 BIOMINERAL TISSUE DEVELOPMENT 5 75 0.001664 0.008478
916 COCHLEA MORPHOGENESIS 3 21 0.001671 0.008478
917 NEGATIVE REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION 3 21 0.001671 0.008478
918 MULTICELLULAR ORGANISM GROWTH 5 76 0.001765 0.008944
919 EAR MORPHOGENESIS 6 112 0.001801 0.009109
920 RESPONSE TO AMINO ACID 6 112 0.001801 0.009109
921 REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY 5 77 0.00187 0.009416
922 PROTEIN LOCALIZATION TO ORGANELLE 15 556 0.001867 0.009416
923 REGULATION OF BMP SIGNALING PATHWAY 5 77 0.00187 0.009416
924 CELLULAR MACROMOLECULE LOCALIZATION 26 1234 0.001868 0.009416
925 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 7 153 0.001895 0.009535
926 REGULATION OF ANDROGEN RECEPTOR SIGNALING PATHWAY 3 22 0.001919 0.009589
927 NEGATIVE REGULATION OF MACROAUTOPHAGY 3 22 0.001919 0.009589
928 RESPONSE TO THYROID HORMONE 3 22 0.001919 0.009589
929 REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR 3 22 0.001919 0.009589
930 EMBRYONIC PLACENTA MORPHOGENESIS 3 22 0.001919 0.009589
931 HISTONE H3 DEACETYLATION 3 22 0.001919 0.009589
932 ADAPTIVE IMMUNE RESPONSE BASED ON SOMATIC RECOMBINATION OF IMMUNE RECEPTORS BUILT FROM IMMUNOGLOBULIN SUPERFAMILY DOMAINS 7 154 0.001967 0.009809
933 POSITIVE REGULATION OF PEPTIDASE ACTIVITY 7 154 0.001967 0.009809
934 POSITIVE REGULATION OF ENDOCYTOSIS 6 114 0.00197 0.009816
935 RESPONSE TO ANTIBIOTIC 4 47 0.001998 0.009945
NumGOOverlapSizeP ValueAdj. P Value
1 RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING 51 629 5.142e-29 4.777e-26
2 REGULATORY REGION NUCLEIC ACID BINDING 54 818 2.391e-26 1.111e-23
3 TRANSCRIPTION FACTOR BINDING 42 524 1.136e-23 3.518e-21
4 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 60 1199 4.667e-23 1.084e-20
5 SEQUENCE SPECIFIC DNA BINDING 55 1037 2.974e-22 5.526e-20
6 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING 28 315 3.672e-17 5.686e-15
7 DOUBLE STRANDED DNA BINDING 41 764 9.208e-17 1.222e-14
8 ENZYME BINDING 62 1737 1.774e-16 2.06e-14
9 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 26 328 8.282e-15 8.549e-13
10 CHROMATIN BINDING 29 435 1.937e-14 1.799e-12
11 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 20 226 1.57e-12 1.326e-10
12 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II DISTAL ENHANCER SEQUENCE SPECIFIC BINDING 14 90 1.763e-12 1.365e-10
13 KINASE BINDING 31 606 2.656e-12 1.898e-10
14 RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING 14 104 1.348e-11 8.944e-10
15 MACROMOLECULAR COMPLEX BINDING 47 1399 1.52e-11 9.413e-10
16 PROTEIN DIMERIZATION ACTIVITY 39 1149 8.296e-10 4.568e-08
17 TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING 27 588 8.36e-10 4.568e-08
18 TRANSCRIPTIONAL REPRESSOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING 15 168 9.279e-10 4.789e-08
19 CORE PROMOTER PROXIMAL REGION DNA BINDING 21 371 1.852e-09 9.056e-08
20 CORE PROMOTER BINDING 14 152 2.276e-09 1.057e-07
21 RECEPTOR BINDING 44 1476 3.275e-09 1.449e-07
22 ACTIVATING TRANSCRIPTION FACTOR BINDING 9 57 1.553e-08 6.56e-07
23 BETA CATENIN BINDING 10 84 4.022e-08 1.625e-06
24 TRANSCRIPTION COACTIVATOR ACTIVITY 17 296 5.569e-08 2.156e-06
25 SMAD BINDING 9 72 1.267e-07 4.709e-06
26 IDENTICAL PROTEIN BINDING 35 1209 3.429e-07 1.225e-05
27 MOLECULAR FUNCTION REGULATOR 36 1353 1.676e-06 5.766e-05
28 G PROTEIN COUPLED RECEPTOR BINDING 14 259 1.754e-06 5.819e-05
29 FRIZZLED BINDING 6 36 3.007e-06 9.634e-05
30 HISTONE DEACETYLASE BINDING 9 105 3.232e-06 0.0001001
31 REPRESSING TRANSCRIPTION FACTOR BINDING 7 57 3.717e-06 0.0001114
32 PROTEIN KINASE ACTIVITY 22 640 4.447e-06 0.0001291
33 STEROID BINDING 8 91 9.51e-06 0.0002598
34 PROTEIN HOMODIMERIZATION ACTIVITY 23 722 9.278e-06 0.0002598
35 HISTONE LYSINE N METHYLTRANSFERASE ACTIVITY 6 45 1.154e-05 0.0003064
36 HISTONE ACETYLTRANSFERASE BINDING 5 28 1.462e-05 0.0003773
37 GLYCOPROTEIN BINDING 8 101 2.051e-05 0.0005015
38 CORE PROMOTER SEQUENCE SPECIFIC DNA BINDING 8 101 2.051e-05 0.0005015
39 TRANSCRIPTIONAL REPRESSOR ACTIVITY RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING 6 53 3.016e-05 0.0007004
40 RNA POLYMERASE II CORE PROMOTER SEQUENCE SPECIFIC DNA BINDING 6 53 3.016e-05 0.0007004
41 TRANSMEMBRANE RECEPTOR PROTEIN KINASE ACTIVITY 7 81 3.878e-05 0.0008787
42 LYSINE N METHYLTRANSFERASE ACTIVITY 6 57 4.59e-05 0.001015
43 HISTONE METHYLTRANSFERASE ACTIVITY 6 58 5.071e-05 0.001096
44 RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING 5 36 5.207e-05 0.001099
45 UBIQUITIN LIKE PROTEIN LIGASE BINDING 12 264 5.382e-05 0.001111
46 N METHYLTRANSFERASE ACTIVITY 7 88 6.619e-05 0.001337
47 GROWTH FACTOR BINDING 8 123 8.438e-05 0.001668
48 TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE ACTIVITY 6 64 8.874e-05 0.001717
49 ENHANCER BINDING 7 93 9.414e-05 0.001785
50 RNA POLYMERASE II DISTAL ENHANCER SEQUENCE SPECIFIC DNA BINDING 6 65 9.684e-05 0.001799
51 KINASE ACTIVITY 23 842 0.0001003 0.001827
52 GLYCOSAMINOGLYCAN BINDING 10 205 0.0001271 0.002271
53 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING 8 133 0.0001456 0.002553
54 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 25 992 0.0001753 0.003016
55 PROTEIN TYROSINE KINASE ACTIVITY 9 176 0.0001942 0.003281
56 TRANSCRIPTIONAL REPRESSOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 7 105 0.0002015 0.003343
57 CHEMOATTRACTANT ACTIVITY 4 27 0.0002349 0.003829
58 HISTONE DEACETYLASE ACTIVITY H3 K14 SPECIFIC 3 12 0.0002981 0.004775
59 PROTEIN METHYLTRANSFERASE ACTIVITY 6 82 0.0003496 0.005505
60 TRANSCRIPTIONAL REPRESSOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING 6 86 0.000452 0.006999
61 RECEPTOR ACTIVATOR ACTIVITY 4 32 0.0004604 0.007011
62 STEROID HORMONE RECEPTOR ACTIVITY 5 59 0.0005591 0.008377
63 E BOX BINDING 4 34 0.0005832 0.008601
64 PLATELET DERIVED GROWTH FACTOR RECEPTOR BINDING 3 15 0.0006012 0.008727
65 ENZYME REGULATOR ACTIVITY 23 959 0.0006388 0.00913
66 HORMONE RECEPTOR BINDING 8 168 0.0007036 0.009903
NumGOOverlapSizeP ValueAdj. P Value
1 TRANSCRIPTION FACTOR COMPLEX 19 298 1.611e-09 9.407e-07
2 CELL SURFACE 28 757 4.431e-08 1.294e-05
3 NUCLEAR CHROMATIN 15 291 1.349e-06 0.0002625
4 CHROMATIN 18 441 3.352e-06 0.0004894
5 MEMBRANE REGION 30 1134 1.52e-05 0.001775
6 NEURON PART 32 1265 1.882e-05 0.001832
7 PLASMA MEMBRANE REGION 26 929 2.293e-05 0.001913
8 EXTRACELLULAR MATRIX 16 426 3.284e-05 0.001918
9 POSTSYNAPSE 15 378 3.103e-05 0.001918
10 NEURON PROJECTION 26 942 2.902e-05 0.001918
11 MEMBRANE MICRODOMAIN 12 288 0.000123 0.006531
12 CHROMOSOME 23 880 0.0001913 0.008177
13 TRANSCRIPTIONAL REPRESSOR COMPLEX 6 74 0.0001995 0.008177
14 PROTEINACEOUS EXTRACELLULAR MATRIX 13 356 0.000238 0.008177
15 CELL SUBSTRATE JUNCTION 14 398 0.0002025 0.008177
16 CELL PROJECTION PART 24 946 0.0002153 0.008177
17 SYNAPSE PART 18 610 0.0002322 0.008177

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 Hippo_signaling_pathway_hsa04390 19 154 1.376e-14 7.156e-13
2 Wnt_signaling_pathway_hsa04310 15 146 1.275e-10 3.315e-09
3 Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 14 139 6.988e-10 1.211e-08
4 MAPK_signaling_pathway_hsa04010 19 295 1.361e-09 1.77e-08
5 Cellular_senescence_hsa04218 14 160 4.446e-09 4.624e-08
6 Hedgehog_signaling_pathway_hsa04340 8 47 5.411e-08 4.689e-07
7 FoxO_signaling_pathway_hsa04068 11 132 3.43e-07 2.548e-06
8 PI3K_Akt_signaling_pathway_hsa04151 16 352 3.068e-06 1.994e-05
9 p53_signaling_pathway_hsa04115 7 68 1.226e-05 7.081e-05
10 mTOR_signaling_pathway_hsa04150 9 151 6.035e-05 0.0003138
11 Focal_adhesion_hsa04510 10 199 9.95e-05 0.0004496
12 Jak_STAT_signaling_pathway_hsa04630 9 162 0.0001037 0.0004496
13 Apelin_signaling_pathway_hsa04371 8 137 0.0001787 0.0006978
14 Apoptosis_hsa04210 8 138 0.0001879 0.0006978
15 Ras_signaling_pathway_hsa04014 10 232 0.0003446 0.001195
16 Cell_cycle_hsa04110 7 124 0.0005556 0.001806
17 Rap1_signaling_pathway_hsa04015 9 206 0.0006158 0.001884
18 TNF_signaling_pathway_hsa04668 6 108 0.001496 0.004321
19 Cytokine_cytokine_receptor_interaction_hsa04060 9 270 0.003934 0.01077
20 Sphingolipid_signaling_pathway_hsa04071 5 118 0.01139 0.02827
21 Necroptosis_hsa04217 6 164 0.01142 0.02827
22 Oocyte_meiosis_hsa04114 5 124 0.01389 0.03282
23 Endocytosis_hsa04144 7 244 0.02217 0.05013
24 NF_kappa_B_signaling_pathway_hsa04064 4 95 0.0234 0.0507
25 cAMP_signaling_pathway_hsa04024 6 198 0.02625 0.0546
26 Regulation_of_actin_cytoskeleton_hsa04810 6 208 0.0323 0.0646
27 Mitophagy_animal_hsa04137 3 65 0.03811 0.07269
28 cGMP_PKG_signaling_pathway_hsa04022 5 163 0.03914 0.07269
29 Hippo_signaling_pathway_multiple_species_hsa04392 2 29 0.04294 0.07699
30 Tight_junction_hsa04530 5 170 0.04549 0.07886
31 AMPK_signaling_pathway_hsa04152 4 121 0.04987 0.08365
32 TGF_beta_signaling_pathway_hsa04350 3 84 0.07123 0.1157
33 Cell_adhesion_molecules_.CAMs._hsa04514 4 145 0.08446 0.1331
34 Notch_signaling_pathway_hsa04330 2 48 0.1038 0.1588
35 Autophagy_animal_hsa04140 3 128 0.1798 0.2671
36 ECM_receptor_interaction_hsa04512 2 82 0.2401 0.3468
37 Gap_junction_hsa04540 2 88 0.2654 0.373
38 Phosphatidylinositol_signaling_system_hsa04070 2 99 0.3118 0.4108
39 HIF_1_signaling_pathway_hsa04066 2 100 0.316 0.4108
40 Calcium_signaling_pathway_hsa04020 3 182 0.3438 0.436
41 Phospholipase_D_signaling_pathway_hsa04072 2 146 0.4976 0.588
42 Neuroactive_ligand_receptor_interaction_hsa04080 3 278 0.6168 0.6897

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1 LINC00337 hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7d-5p;hsa-let-7e-5p;hsa-let-7f-5p;hsa-let-7g-5p;hsa-miR-139-5p;hsa-miR-150-3p;hsa-miR-26a-5p;hsa-miR-320a 10 EZH2 Sponge network 2.531 1.0E-5 2.636 0 0.468
2 TMPO-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7e-5p;hsa-let-7f-5p;hsa-let-7g-5p;hsa-miR-101-3p;hsa-miR-139-5p;hsa-miR-150-3p;hsa-miR-214-3p;hsa-miR-26a-5p 10 EZH2 Sponge network 1.344 0.00035 2.636 0 0.425
3 LUCAT1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7d-5p;hsa-let-7e-5p;hsa-let-7f-5p;hsa-let-7g-5p;hsa-miR-101-3p;hsa-miR-139-5p;hsa-miR-150-3p;hsa-miR-26a-5p;hsa-miR-320a 11 EZH2 Sponge network 3.001 0 2.636 0 0.412
4 RP5-1120P11.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7d-5p;hsa-let-7e-5p;hsa-let-7f-5p;hsa-let-7g-5p;hsa-miR-101-3p;hsa-miR-139-5p;hsa-miR-150-3p;hsa-miR-26a-5p 10 EZH2 Sponge network 1.924 1.0E-5 2.636 0 0.394
5 RNF144A-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7d-5p;hsa-let-7f-5p;hsa-let-7g-5p;hsa-miR-101-3p;hsa-miR-139-5p;hsa-miR-150-3p;hsa-miR-26a-5p;hsa-miR-320a 10 EZH2 Sponge network 1.592 0.00021 2.636 0 0.394
6 CTD-2357A8.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7d-5p;hsa-let-7f-5p;hsa-let-7g-5p;hsa-miR-101-3p;hsa-miR-139-5p;hsa-miR-150-3p;hsa-miR-26a-5p;hsa-miR-320a 10 EZH2 Sponge network 2.725 0 2.636 0 0.299

Quest ID: 1c390bd8f8202d130687ff2a87e71eeb